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Biotin is an essential cofactor utilized by all domains of life, but only 
synthesized by bacteria, fungi and plants, making biotin biosynthesis a target 
for antimicrobial development. We executed a genetic screen in 
Mycobacterium smegmatis and identified pyruvate carboxylase (Pyc) as 
required for biotin biosynthesis. pyc::tn fails to transcriptionally induce late 
stage biotin biosynthetic genes in low biotin conditions. Loss of the repressor 
bioQ in pyc::tn reverted biotin auxotrophy, as did reconstituting the pathway 
through heterologous expression of BioB and provision of DTB. The role of 
Pyc in biotin regulation required its catalytic activities and could be supported 
by M. tuberculosis Pyc. Pyc is the most rapidly depleted biotinylated protein 
after biotin withdrawal, indicating that it is a sensitive indicator of this state. 
Metabolomics revealed several dysregulated metabolites that could mediate 
BioQ derepression. Our data indicate that mycobacterial cells monitor biotin 
sufficiency through a metabolic signal generated by dysfunction of a 
biotinylated protein of central metabolism.  
 
 
 
Rip1 is a site-2 protease required for full virulence in the mouse, but the 
causes of this phenotype have yet to be elucidated. We tested Δrip1 for 
defects in models of host-mediated stress and found that it is sensitive to nitric 
oxide (NO), hypoxia, and multiple classes of antibiotics. Further examination of 
the determinants of these sensitivities demonstrated differing requirements for 
Rip1 functions and substrates in each of these models. Δrip1 is not defective 
for induction of the DosR regulon, which links NO and hypoxia. Further, we 
reversed the Δrip1 sensitivity to antibiotics with addition of NaHS, but were 
unable to do so for NO or diamide.  
To determine the contribution of NO to the Δrip1 in vivo phenotype, we 
infected nos2-/- mice with Δrip1. Δrip1 regained much of its virulence in nos2-/- 
mice, but did not recapitulate WT fully, indicating a partial role for NO. These 
mice developed granulomatous lesions, which are atypical of the murine 
model. Histopathological examinations demonstrated that these lesions 
possess numerous traits found in human pathology. We suggest that infection 
of nos2-/- with attenuated strains such as Δrip1 may be a useful model for 
studying the granuloma.
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CHAPTER ONE: INTRODUCTION 
 
Biotin biosynthesis has been incompletely characterized in 
Mycobacterium smegmatis* 
Biotin (vitamin B7, or vitamin H) is an essential cofactor used by the 
carboxylase and decarboxylase family of enzymes. Whereas biotin is vital to 
and used by members of all domains of life, it is synthesized only by bacteria, 
plants, and fungi (Lin and Cronan 2011). For this reason, biotin biosynthesis 
has been proposed as a promising target for antibiotic development. In the 
human pathogen M. tuberculosis, depletion of the essential biotin biosynthetic 
protein BioA leads to bactericidality in vitro and clearance of M. tuberculosis 
from mice when BioA is depleted either in acute or persistent infection (Woong 
Park et al. 2011). The antibiotic amiclenomycin and its analogues inhibit BioA 
and show whole-cell activity against M. tuberculosis (Shi et al. 2011), and a 
target-based approach identified novel compounds with inhibitory activity 
against BioA (Park et al. 2015), many of which were also present in the 
diversity-oriented scaffolds (DOS) collection (Galloway, Isidro-Llobet, and 
Spring 2010). Further characterization of the biotin biosynthetic pathway may 
reveal additional antibiotic targets. 
The latter stages of biotin biosynthesis are conserved among all organisms 
proficient for biotin biosynthesis. Pimeloyl-ACP/CoA is converted to biotin via 
the sequential action of four enzymes: BioF, BioA, BioD, and BioB. Thus far, 
no alternative pathway has been identified to perform this stage of biotin 
biosynthesis. In contrast, multiple different mechanisms have been shown to 
yield pimeloyl-ACP. In E. coli, the methyltransferase BioC allows malonyl-ACP 
                                                          
* This section is derived from: Lazar et al 2017 (in review) 
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to enter the fatty acid elongation pathway, and after two rounds of elongation, 
pimeloyl-ACP methyl ester exits the pathway when it is hydrolyzed by the 
methyl esterase BioH (Lin, Hanson, and Cronan 2010). B. subtilis has a 
cytochrome P450 enzyme (BioI) that can convert long-chain fatty acids to 
pimeloyl-ACP, and also possesses a pathway which converts free pimelic acid 
to pimeloyl-CoA using the enzyme BioW (Cryle 2010, Lin and Cronan 2011) 
(Summarized in Figure 1). Recent evidence indicates that BioW is the 
dominant pathway in B. subtilis (Manandhar and Cronan, 2017). 
As biotin biosynthesis is an energetically costly process, many biotin 
prototrophs have evolved mechanisms to control the transcription of biotin 
biosynthetic genes such that expression is induced when exogenous biotin is 
not available. E. coli possesses a bifunctional biotin ligase BirA, which acts as 
a biotin ligase to covalently attach biotin to biotin-utilizing enzymes, and as a 
transcriptional regulator of biotin biosynthesis (Cronan 1988). In biotin-replete 
conditions, BirA forms a homodimer, which binds the biotin operator and 
represses the transcription of bioFADBC. In biotin-starved conditions, 
unbiotinylated biotin binding proteins (AccB) competitively bind to single BirA 
proteins to form BirA-AccB heterodimers, which do not possess repressor 
activity (Chakravartty and Cronan 2012, Solbiati and Cronan 2010, Weaver et 
al. 2001). As such, in E. coli, biotin biosynthesis is coupled to the accumulation 
of an unbiotinylated protein through the bifunctional BirA.  
In contrast, Brucella and other Alphaproteobacteria utilize the GntR family 
protein BioR to repress expression of bioFADBZ and of the biotin transporter 
bioY during biotin-replete conditions (Feng, Zhang, and Cronan 2013, Feng et 
al. 2013). The mechanism of this repression is poorly understood, but Brucella 
(type I, or unifunctional) BirA lacks the DNA-binding domain found in E. coli  
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Figure 1: Summary of previously-characterized biotin biosynthetic 
pathway. 
Late (green box) biotin biosynthesis is conserved in all biotin-synthesizing 
organisms and is catalyzed by the action of four enzymes: BioF, BioA, BioD, 
and BioB, which convert pimeloyl-ACP/CoA to Biotin. Synthesis of the 
pimeloyl-ACP moiety differs between bacteria. In E. coli (red box), BioC 
methylates malonyl-ACP to form malonyl-ACP methyl ester, which then enters 
the fatty-acid elongation pathway. BioH  demethylates pimeloyl-ACP methyl 
ester to form pimeloyl-ACP (Lin, Hanson, and Cronan 2010). In contrast, B. 
subtilis (blue box) utilizes BioI to break down long-chain fatty acids into 
pimeloyl-ACP. A secondary pathway exists in which free pimelic acid is 
converted to pimeloyl-ACP by BioW (Cryle 2010). 
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BirA (Beckett 2007). Along with many other Actinobacteria, Mycobacteria also 
possess a type I BirA protein, and the soil bacterium M. smegmatis has 
recently been discovered to employ the TetR family protein BioQ as a 
transcriptional regulator of bioFDB expression (Tang et al. 2014). TetR family 
proteins typically repress transcription in the absence of their ligand, and 
dissociate from DNA after ligand binding triggers a conformational shift in their 
helix-turn-helix DNA binding domain (Ramos et al. 2005). As is the case in 
Alphaproteobacteria, the mechanism of BioQ derepression is poorly 
characterized, though it has been shown that biotin itself is not the ligand of 
BioQ (Tang et al. 2014), suggesting that some alternate non-biotin ligand 
mediates BioQ release from its operator. Although TetR like repressors are 
abundant in M. tuberculosis, it lacks a predicted ortholog to BioQ and the 
transcriptional regulation of biotin in M. tuberculosis has not been elucidated 
(summarized in Figure 2). 
In this study we undertook a genetic screen in M. smegmatis for biotin 
auxotrophs. In addition to identifying previously known late stage biotin 
biosynthetic genes, we identified multiple transposon insertions in pyruvate 
carboxylase (pyc) as conferring biotin auxotrophy. Analysis of pyc null strains 
supports a model in which dysfunction of Pyc during biotin depletion, itself a 
biotin dependent enzyme, generates a metabolic signal that stimulates BioQ 
derepression.  
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Figure 2: Summary of transcriptional regulation of biotin biosynthesis 
E. coli (left) possesses a bifunctional biotin ligase (BirA) which is responsible 
for both the attachment of biotin to and for transcriptional regulation of biotin 
biosynthesis. When biotin-binding proteins are saturated with biotin BirA forms 
a homodimer with repressive function. When biotin is absent, unbiotinylated 
(i.e. apo-) biotin-binding proteins bind to BirA and relieve its repressive activity. 
(Beckett 2007) Brucella and M. smegmatis possess a biotin ligase with no 
repressive activity. Brucella (center) utilizes the repressor BioR to regulate 
transcription of biotin biosynthetic genes. In the absence of biotin, BioR binds 
its ligand and transcription is derepressed (Feng, Zhang, and Cronan 2013, 
Feng et al. 2013). M. smegmatis (right) utilizes BioQ to repress biotin 
transcription in the presence of biotin. In the absence of biotin, BioQ binds to 
its ligand and transcription is derepressed (Tang et al. 2014).  
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Rip1 is a site-2 protease essential for M. tuberculosis virulence 
M. tuberculosis is a human pathogen with global health relevance (Sia and 
Wieland 2011, Raviglione and Sulis 2016, Zaman 2010, Gupta, Espinal, and 
Raviglione 2004).  Upon being transmitted via the aerosol route, M. tb is 
internalized within the phagosome of the alveolar macrophage, where it is 
subject to numerous host-mediated stresses (van Crevel, Ottenhoff, and van 
der Meer 2002, Bordbar et al. 2010). Despite being localized to this 
environment, M. tb is nonetheless able to avoid killing and to establish either a 
latent or active infection (Goldberg, Saini, and Porcelli 2014, Behar, Divangahi, 
and Remold 2010, Stallings and Glickman 2010). Our interest is to examine 
one of the mechanisms M. tb utilizes to sense and to respond to host-
mediated stresses. 
The site-2 protease (S2P) family of proteins is utilized throughout the bacterial 
domain in the process of regulated intramembrane proteolysis (RIP) as part of 
a signal transduction pathway in order to produce a transcriptional response to 
stress in the periplasm or outside of the cell (Schneider and Glickman 2013, 
Rudner, Fawcett, and Losick 1999). S2Ps are intramembrane proteases; that 
is, they cleave a membrane protein at a site inside or directly adjacent to the 
plasma membrane (Urban 2009). Upon the initiation of stress, a site-1 
protease (S1P) cleaves a membrane protein at a site in the periplasm. This 
proteolytic cleavage converts this membrane protein into a substrate for the 
site-2 protease, which then further cleaves it at a site in the plasma 
membrane. The cleavage event catalyzed by the site-2 protease releases the 
intracellular section of the membrane protein from the membrane, and with it a 
peripheral membrane protein which had been tethered to the membrane with 
it. This allows the peripheral protein to translocate to the chromosome and to 
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bind to its cognate promoter, where it acts as a transcription factor and drives 
a transcriptional response to the stress which initiated the beginning S1P 
cleavage event. 
One of the best-studied RIP pathways is the DegS/RseP pathway in E. coli. 
The S1P DegS cleaves the anti-sigma factor anti-σE (RseA) in response to 
mislocalized membrane proteins or unfolded proteins in the periplasm (Chaba 
et al. 2011). RseA is then cleaved by the site-2 protease RseP (Koide, Ito, and 
Akiyama 2008), which releases σE (RpoE) from the membrane whereupon it 
acts as a transcription factor (Rhodius et al. 2006). RpoE is a member of the 
extracytoplasmic function (ECF) family of sigma factors which drives the 
transcription of several genes (Helmann 2002, Heinrich and Wiegert 2009). 
Previous work in the Glickman lab identified three members of the S2P family 
in M. tb via homology search, and further demonstrated that one of these 
proteins--Rip1 (Rv2869c)-- was essential for virulence, while the other two 
members are each dispensable (Makinoshima and Glickman 2005). A Δrip1 
null mutant was highly attenuated for virulence in both the acute and the 
persistence phases of mouse infection. Further work showed that four anti-
sigma factors: anti-σK, σL, σM, and σD were substrates of Rip1 (Sklar et al. 
2010, Schneider, Sklar, and Glickman 2014), though genes outside the union 
of these four sigma factor operons remain. Additionally, a ΔσK/σL/σM triple 
mutant failed to recapitulate the Δrip1 mouse phenotype (Schneider, Sklar, 
and Glickman 2014). While a ΔσK/σL/σM/σD mutant has yet to be constructed or 
tested, these data indicate that we have yet to uncover the full mechanism of 
Rip1-mediated gene regulation. Additional work in the Glickman lab 
characterized the role of the protein-binding PDZ domain (Kroos and Akiyama 
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2013, Walsh et al. 2003) in both tethering substrates to Rip1 and additionally 
as a negative regulator of Rip1 function (Schneider et al. 2013). 
Below, we describe our attempt to understand the role of Rip1 in M. tb 
virulence from a new perspective. We directly test Δrip1 M. tb for defects in 
various in vitro models of host-mediated stress. We find that the Δrip1 strain is 
attenuated when treated with the nitric oxide donor DETA-NO, as well as in 
the Wayne model of anaerobiosis. Additionally, we found that Δrip1 is 
susceptible to multiple classes of antibiotic. We analyze the contributions of 
sigma factors, Rip1 catalytic activity, and the PDZ domain to these 
phenotypes. 
 
The phenotype of Δrip1 M. tuberculosis in nos2-/- mice 
While Δrip1 M. tb shows a striking defect in the mouse model of infection, this 
model may understate or misrepresent the role of Rip1. The granuloma—or 
tubercule—is the hallmark of pulmonary infection in human disease (Guirado 
and Schlesinger 2013, Ehlers and Schaible 2012). It is controversial whether 
the granuloma is a mechanism of host control of the pathogen or whether it is 
induced by the pathogen to enable virulence; there is growing evidence that 
both of these are true and that the granuloma is the result of a complex 
interplay between host and pathogen (Silva Miranda et al. 2012, 
Ramakrishnan 2012, Rubin 2009). However, it is clear that the mouse, which 
is not a host for M. tuberculosis in the wild, does not form granulomas in 
response to M. tb infection, while other models including guinea pigs, 
zebrafish, and nonhuman primates do develop these lesions (Pozos and 
Ramakrishnan 2004, Via et al. 2008). For reasons of practicality, expense, and 
because mouse genetics have been well-characterized—specifically with 
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respect to the mouse immune system—the mouse model remains one of the 
primary tools used to study the virulence of M. tb and the host immune 
response to it.  
Human granulomas have numerous characteristics which distinguish 
themselves from non-granulomatous lesions. Granulomas possess a distinct 
organization of immune subsets from center to periphery, with the center of 
the lesion comprised of mostly macrophages and the periphery containing 
lymphocytes and dendritic cells, along with foamy macrophages (Guirado and 
Schlesinger 2013, Russell et al. 2009, Ehlers and Schaible 2012). Along with 
its immune organization, these lesions are typified by fibrosis surrounding the 
outside of the granuloma (Solsona Peiro, de Souza Galvao, and Altet Gomez 
2014, Subbian et al. 2011). The center of the lesion may be cellular, necrotic, 
or cavitating (Ehlers and Schaible 2012), wit h the development of hypoxia 
also seen as a hallmark of the granuloma and specifically as a means of host 
control of the pathogen(Datta et al. 2016, Rustad et al. 2009, Via et al. 2008). 
Mouse models of infection which do not recapitulate hypoxia specifically may 
be a poor choice for elucidating certain aspects of the Δrip1 defect.  
As we found that Δrip1 is susceptible to the nitric oxide donor DETA-NO in an 
in vitro model, we infected nos2-/- (iNOS knockout) mice with Δrip1 to 
determine the contribution of nitric oxide to the Δrip1 in vivo phenotype. The 
iNOS knockout mouse has been well-studied as a means of showing the 
relevance of nitric oxide Δrip1 virulence was significantly, but not totally 
restored. Surprisingly, iNOS knockout mice developed granulomatous lesions 
rather than the non-granulomatous lesions typical of mouse infections. Further 
work characterizing these granulomas showed that they indeed demonstrate 
several aspects of pathology found in humans and non-mouse mammals.   
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CHAPTER TWO: A METABOLIC SIGNAL FOR LOW BIOTIN 
TRANSCRIPTIONAL INDUCTION MEDIATED BY PYRUVATE 
CARBOXYLASE IN MYCOBACTERIUM SMEGMATIS* 
 
Disruption of MSmeg_2412 confers biotin auxotrophy 
To identify new genes involved in biotin biosynthesis in mycobacteria, we 
employed a forward genetics approach using the mycobacteriophage 
φMycoMarT7. We constructed a library of approximately 10,000 transposon 
insertion mutants in M. smegmatis mc2155 strain, and screened these mutants 
for inability to grow on medium lacking biotin. This strategy identified insertions 
in the previously characterized biotin biosynthetic genes bioA, bioB, and bioF 
as conferring biotin auxotrophy. Three strains, each bearing independent 
transposon insertions in MSmeg_2412, were unable to grow on medium 
lacking biotin (Table 1). MSmeg_2412 encodes pyruvate carboxylase, an 
enzyme of central carbon metabolism not previously implicated in biotin 
biosynthesis. Pyruvate carboxylase converts pyruvate to oxaloacetate utilizing 
biotin as an essential cofactor (Jitrapakdee et al. 2008, Yu et al. 2009), and 
has been shown to have roles in anaplerosis, gluconeogenesis, elongation of 
fatty acids, and branched-chain amino acid biosynthesis (Peters-Wendisch et 
al. 1998, Attwood 1995, Sauer and Eikmanns 2005, Owen, Kalhan, and 
Hanson 2002, Mukhopadhyay and Purwantini 2000).. 
We proceeded to confirm that disruption of pyruvate carboxylase itself, rather 
than second-site mutations or polar effects, was responsible for the inability of 
pyruvate carboxylase insertion mutants to grow on medium lacking biotin. To 
do so, we complemented these strains with plasmids expressing  
                                                          
* This chapter is derived from: Lazar et al 2017 (in review) 
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Table 1: Biotin auxotrophic Transposon mutants.  
 
Mutant # MGM # gene Gene 
length  
(NT) 
Nucleotide 
at tn 
insertion 
orientation of tn  
(relative to 
coding 
sequence) 
10 8001 MSmeg 
_2412 
3381 2061-2062 sense 
35 8002 bioB 3186 443-444 sense 
43 8003 bioF 1146 132-133 antisense 
67 8003 bioF 1146 132-133 antisense 
86 8004 bioA 1296 1211-1212 antisense 
112 8004 bioA 1296 1211-1212 antisense 
119 8005 MSmeg 
_2412 
3381 1358-1357 antisense 
130 8004 bioA 1296 1211-1212 antisense 
134 8006 MSmeg 
_2412 
3381 2470-2471 antisense 
 
 
MSmeg_2412 or expressing the downstream genes MSmeg_2413 and 
MSmeg_2414. Expression of MSmeg_2412 restored biotin prototrophy to the 
pyc::tn strain, whereas neither expression of MSmeg_2413 nor MSmeg_2414 
had any effect (Figure 3A).   
To further assess the biotin auxotrophy in the pyc::tn strain, we grew wild type 
M. smegmatis, pyc::tn, and bioA::tn in liquid medium containing decreasing  
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Figure 3: A transposon insertion in MSMEG_2412 (pyruvate carboxylase) 
impairs growth on medium lacking biotin. 
(A) Growth of WT M. smegmatis (MGM8007), pyc::tn (MGM8008) bioA::tn 
(MGM8009) and bioB::tn (MGM8010), and pyc::tn complemented with 
MSMEG_2412 (MGM8011), MSMEG_2413 (MGM8012), or MSMEG_2414 
(MGM8013) on biotin containing (left) or biotin free (right) media. Rows are 
ten-fold serial dilutions. EV=empty vector. (B-D) Growth of WT (B), bioA::tn 
(C), and pyc::tn (D) in biotin-replete medium (500 ng/mL, dark blue), medium 
with decreasing concentrations of biotin (50 ng/mL: light blue; 5 ng/mL: green; 
0.5 ng/mL: yellow), and biotin-deficient medium (orange). Each line is the 
mean of three biological replicates. (E) Survival during biotin depletion. WT 
(circles), bioA::tn (squares), and pyc::tn (triangles) were grown in medium 
containing (solid lines) or lacking biotin (dashed lines), and viable CFU was 
assessed by culturing serial dilutions on agar media. Error bars are standard 
deviations of three biological replicates. 
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concentrations of biotin. Wild type M. smegmatis did not show an identifiable 
defect at any biotin concentration, whereas both pyc::tn and bioA::tn grew 
similarly well in medium containing 1x (500 ng/mL), 1/10x, or 1/100x biotin, but 
failed to grow after approximately 12 hours in medium containing either no 
biotin or 1/1000x biotin (Figure 3B-D). Quantitation of cell death indicated that 
both pyc::tn and bioA::tn lose viability with similar kinetics, beginning at 12 
hours after biotin withdrawal (Figure 3E). These data indicate that loss of 
pyruvate carboxylase confers biotin auxotrophy in mycobacteria with a biotin 
requirement for viability similar to a known late stage biotin biosynthetic defect.  
 
Pyruvate carboxylase is required for transcriptional derepression of 
biotin biosynthesis 
Given the similar phenotype of the pyc::tn and bioA::tn mutants, we tested 
whether pyc::tn was defective in the late stages of biotin biosynthesis. Addition 
of desthiobiotin (DTB), the penultimate biosynthetic intermediate in the biotin 
biosynthetic pathway (Figure 1), was unable to restore growth to pyc::tn, 
indicating a defect in bioB function (Figure 4A).  DTB was unsurprisingly able 
to restore growth to bioA::tn strain due to intact BioB function (Figure 4C, right 
panels). Expression of bioB restored biotin prototrophy to pyc::tn when the 
growth medium was supplemented with DTB (Figure 4C, bottom right), but 
only partially restored growth in the absence of DTB (Figure 4C, bottom left), 
indicating that the pool of DTB in the pyc::tn strain is limiting and implying an 
additional defect in the biotin biosynthetic pathway before the generation of 
DTB.  
Biotin biosynthetic genes are transcriptionally induced in low biotin conditions 
such that bioBFD are coordinately regulated. To examine whether 
16 
 
 
 
 
 
Figure 4: pyc::tn is defective in late-stage biotin biosynthesis. 
(A) pathway of late-stage biotin biosynthesis. Pimeloyl-CoA is converted to 
biotin via the action of four biotin biosynthetic enzymes: BioF, BioA, BioD, and 
BioB. Expression of bioFD and of bioB, but not of bioA, has been shown (Tang 
et al. 2014) to be repressed by the TetR-family repressor BioQ under biotin-
replete conditions in M. smegmatis. (B, C) WT (MGM8019), bioA::tn 
(MGM8021), and pyc::tn (MGM8020) were tested for growth on medium 
containing (B), or lacking biotin (C, left panels) or containing the biosynthetic 
intermediate desthiobiotin (DTB) (C; two rightmost panels). bioA::tn and 
pyc::tn strains expressing bioA (pyc::tn: (MGM8034)); bioA::tn: (MGM8036) or 
bioB (pyc::tn: (MGM8035); bioA::tn: (MGM8037)) under the control of a 
heterologous promoter responsive to the inducer anhydrotetracycline (ATc) (C; 
ATc present in bottom panels) were also tested. 
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transcriptional upregulation of these genes is defective in the pyc::tn strain, we 
quantitated the mRNAs for bioFADB by RT-qPCR (Figure 5A). In biotin-replete 
conditions, WT and pyc::tn M. smegmatis express similar levels of these 
transcripts.  However, after three hours of biotin deprivation in wild type cells, 
we observed a 16-fold induction of bioB and bioFD (expressed as a single 
transcript) mRNAs (Figure 5A). We do not find bioA to be transcriptionally 
upregulated by low biotin, consistent with previous reports (Tang et al. 2014). 
In contrast, pyc::tn fails to upregulate bioB or bioFD in low biotin, potentially 
explaining its defect in growth in this condition (Figure 5A). Complementation 
of pyc::tn with a wild type copy of pyc, which complemented biotin auxotrophy 
(Figure 3A), restored bioB induction in low biotin and in fact de-repressed bioB 
even in biotin-replete conditions (Figure 5A). These data indicate that pyc is 
required for the transcriptional induction of biotin biosynthetic genes in low 
biotin conditions.  
Previous work (Tang et al. 2014) has shown that bioB and bioFD—but not 
bioA—are repressed by the TetR like regulator BioQ, which binds to an 
operator in the bioB and bioF promoters which overlaps the TSS for these 
genes (Tang et al. 2014).  BioQ dissociates from its operator in low biotin 
conditions, although the signal for BioQ binding or dissociation is not clear and 
does not appear to be biotin itself or biotinoyl-AMP (Tang et al. 2014). To test 
whether the biotin auxotrophy of the pyc::tn strain requires BioQ mediated 
repression, we introduced null mutations in bioQ in both the WT and pyc::tn 
backgrounds using homologous recombination and double counterselection  
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Figure 5: Pyruvate carboxylase is required for BioQ mediated 
derepression of bioFDB. 
(A) Expression of the biotin biosynthetic genes bioFADB in WT (MGM8007), 
pyc::tn (MGM 8008) and complemented (MGM8011) strains under biotin-
replete and biotin-deficient (-bio) conditions. Strains were grown for three 
hours with or without biotin, RNA was prepared, and RT-qPCR was performed 
for the indicated mRNAs. (B) Loss of bioQ suppresses the biotin auxotrophy of 
pyc::tn. Genetic deletions of pyc (MGM6514) and bioQ (MGM6516 and 
MGM6520) were introduced via homologous recombination and double 
counterselection (see strain table), and growth on medium containing or 
lacking biotin was assessed.  (C) Loss of bioQ restores bioB expression to 
pyc::tn. Error bars are standard deviation of three biological replicates. 
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(Barkan, Stallings, and Glickman 2011). We also constructed a null mutation 
of pyc to confirm that biotin auxotrophy was not specific to the pyc::tn 
transposon mutant.  
We tested each of these strains for the ability to grow without biotin and 
observed that a Δpyc strain was indeed a biotin auxotroph (Figure 5B) and 
that deletion of bioQ in the pyc::tn background restored the ability of this strain 
to grow without biotin (Figure 5B). We also constructed a bioQ null mutant via 
CRISPR-mediated chromosomal cleavage (see methods) in the pyc::tn 
background, (Figure 6A). We tested the ability of pyc::tn ∆bioQ and pyc::tn 
bioQ (frameshift) strains to grow without biotin and found that inactivation of 
bioQ reverted the biotin auxotrophy of the pyc::tn strain (Figure 5B and data 
not shown).  
RT-qPCR of bioB mRNA showed that loss of BioQ derepressed BioB 
expression in wild type cells, as reported previously ((Tang et al. 2014), Figure 
5C) and also restored bioB expression in pyc::tn (Figure 5C, Figure 6B). 
These results demonstrate that the biotin auxotrophy conferred by inactivation 
of pyruvate carboxylase is due to inability to derepress biotin biosynthetic 
genes during biotin deprivation and imply that pyruvate carboxylase is required 
for generation of the signal that relieves BioQ mediated repression.  
 
Pyruvate carboxylase catalytic activity is required for its regulatory 
function 
M. smegmatis possesses two genes predicted to code for pyruvate 
carboxylase enzymes: MSmeg_2412, the transposon mutant of which we 
analyze above, and the additional gene MSmeg_6648. Meanwhile, the 
predicted proteome of the pathogenic mycobacterium M. tuberculosis contains  
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Figure 6: Sequence alignment of mutants made in bioQ using CRISPR 
(A) CRISPR-Cas9 was used to generate frameshift mutants in bioQ pyc::tn. 
Candidate bioQ sequences were sequenced and sequences were aligned to 
the native bioQ sequence (top). Identical nucleotides are shaded in gray, while 
nucleotides different from the reference sequence are not shaded. bioQ 
mutant #16 has a single nucleotide insertion of A at the DSB site (B) pyc::tn 
bioQ #16 restores bioB induction to pyc::tn. Error bars are standard deviation 
of three biological replicates. 
23 
 
  
24 
 
a single pyruvate carboxylase encoded by the gene Rv2967c, which is most 
similar in primary amino acid sequence and genomic organization to 
MSmeg_2412.   
The two M. smegmatis pyruvate carboxylase proteins share a high degree of 
similarity (~90%) by amino acid sequence (Figure 7) with conserved amino 
acid residues found to be necessary for enzymatic activity (biotin carboxylase 
activity: E288, N290, R292 (Janiyani et al. 2001); carboxytransferase activity: 
(R532, D533, E566 (Yu et al. 2009, Marchler-Bauer et al. 2017, St Maurice et 
al. 2007)), or biotin attachment (K1093 (Polyak et al. 2001, Kim et al. 2004)). 
To determine whether the pyruvate carboxylases MSmeg_6648 or Rv2967c 
can compensate for loss of pyc (MSmeg_2412), we expressed each of these 
proteins in pyc::tn. Whereas the M. tuberculosis pyruvate carboxylase 
encoded by Rv2967c did complement the biotin biosynthetic defect of pyc::tn, 
MSmeg_6648 failed to complement even when expressed under control of the 
inducible tetON promoter (Figure 8A). However, western blotting did not reveal 
a detectable protein product corresponding to MSmeg_6648 (data not shown). 
These data demonstrate functional conservation between MSmeg_2412 and 
M. tuberculosis Rv2967c.  
To assess whether pyruvate carboxylase activity itself, rather than another 
property of  MSmeg_2412, is required for its biotin regulatory function, we 
expressed truncations of MSmeg_2412 lacking one or more predicted 
domains. Pyruvate carboxylase possesses three major structural domains: the 
N-terminal biotin carboxylase (BC), carboxytransferase (CT), and the C 
terminal biotin binding (BCCP). The transposon insertions we identified as 
conferring biotin auxotrophy were located between the BC domain and the CT   
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Figure 7: Primary amino acid sequence alignment of pyruvate 
carboxylases Rv2967c (M. tuberculosis) and MSMEG_2412 and 6648 (M. 
smegmatis). 
Sequence alignment was performed using the Clustal Omega web form 
(McWilliam et al. 2013, Sievers et al. 2011). Domains were identified by 
homology to the R. etli pyruvate carboxylase (St Maurice et al. 2007). The 
biotin carboxylase (BC) domain is highlighted with a red line above the primary 
sequence, carboxytransferase (CT) with a blue line, and the biotin-binding 
(BCCP) with a green line. Biotin carboxylase catalytic residues (red arrows) 
were identified via homology with the E. coli biotin carboxylase, (Janiyani et al. 
2001) carboxytransferase catalytic residues (blue arrows) were identified via 
homology with the S. aureus pyruvate carboxylase (Yu et al. 2009), and the 
biotin attachment residue (green arrow) was identified via the CDD database 
(Marchler-Bauer et al. 2017). Transposon insertion sites are noted with black 
arrows and annotated with the strain number. 
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domain (mutant 119) or in the CT domain (mutants 10 and 134) C-terminal to 
active site residues (Figure 7, black arrows). The biotin carboxylase domain  
adds a carboxyl group to biotin in the first step of the pyruvate carboxylase 
mechanism, and is essential for pyruvate carboxylase activity (Janiyani et al. 
2001). 
Truncations containing only the MSMEG_2412 biotin carboxylase (BC) or 
carboxytransferase (CT) domains failed to restore growth to pyc::tn on 
medium lacking biotin. Surprisingly, a truncation lacking the BC domain but 
containing both the CT domain and the biotin-binding (BCCP) domain did 
successfully revert the pyc::tn biotin phenotype (Figure 8B). However, 
expression of a BC catalytic mutant (E288K), which we confirmed is both 
expressed and biotinylated (Figure 8D), failed to restore growth to pyc::tn on 
medium lacking biotin (Figure 8C). Expression of each of these constructs in 
the Δpyc strain, which lacks the entire Pyc protein, revealed identical 
requirements for complementation (Figure 8E,F).  
To further address the question of whether pyruvate carboxylase activity is 
responsible for the requirement for pyruvate carboxylase function and relief of 
BioQ repression, we constructed two mutants which lack the MSMEG_2412 
biotin attachment site (K1093L (Polyak et al. 2001) and K1093R (Kim et al. 
2004)). As expected, expression of either of these mutants failed to restore 
growth to pyc::tn (Figure 8C), despite expression of the mutant proteins at wild 
type levels (Figure 8D, HA panel). We were unable to detect biotinylation of 
each of these mutants using streptavidin-HRP, indicating that despite their 
detectable expression, they each failed to be biotinylated (Figure 8D, biotin 
panel).  As covalent linkage of biotin to the biotin-attachment lysine is required 
for pyruvate carboxylase activity (St Maurice et al. 2007), this experiment  
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Figure 8: Pyruvate carboxylase catalytic activity is required for biotin 
prototrophy 
(A) TB Pyruvate carboxylase supports biotin biosynthesis. WT (MGM8019), 
pyc::tn (MGM8020), bioA::tn (MGM8021), and pyc::tn expressing either the 
annotated second pyruvate carboxylase in M. smegmatis (MSmeg_6648) 
(MGM8024) or the M. tuberculosis ortholog Rv2967c (MGM8025) for growth 
on medium lacking biotin. EV=empty vector.  (B) Truncation of Pyc. pyc::tn 
was complemented with plasmids expressing full length pyruvate carboxylase 
(MGM8023), biotin carboxylase (BC) domain (MGM8026), only the 
carboxytransferase (CT) domain (MGM8027), or the CT domain and the 
biotin-binding (BCCP) domains (MGM8028). (C) Pyruvate carboxylase BC 
active site or biotin attachment sites are required for biotin prototrophy. pyc::tn 
was complemented with plasmids expressing full length Pyc with a BC 
catalytic residue mutation (E288K) (MGM8029) or the essential residue for 
covalent attachment of biotin (K1093L/R) (MGM8030/8031). Each strain was 
N-terminally HA-tagged and expressed under the control of an ATc-dependent 
promoter.  (D) Each of the Pyc isoforms from (C) as well as native pyruvate 
carboxylase (MGM8011) were N-terminally HA tagged. Expression of each of 
the mutants (E288K, K1093L/R) was similar to levels of native pyruvate 
carboxylase (Pyc-HA+) when induced with ATc. Low levels of pyruvate 
carboxylase were present in the absence of induction (Pyc-HA-). Detection of 
protein biotinylation was performed using streptavidin-HRP. RNA polymerase 
subunit B (RpoB) is shown as a loading control. Native pyruvate carboxylase 
(Pyc-HA) is the same strain shown in Figure 3A and Figure 5A. (E) Δpyc 
(MGM6521) was complemented with plasmids expressing the BC domain 
(MGM6522), only the CT domain (MGM6523), or the CT domain and BCCP  
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domains (MGM6524). (F) Pyruvate carboxylase BC active site or biotin 
attachment sites are required for biotin prototrophy. Δpyc was complemented 
with plasmids expressing Pyc-E288K (MGM6525) or Pyc-K1093L/R 
(MGM6526/ 2527).  
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provides further evidence that pyruvate carboxylase activity of MSMEG_2412, 
rather than any other function of the protein or its coding sequence, is the key 
factor which is essential for its regulatory function. In addition, the failure of a 
nonbiotinylated Pyc enzyme to induce biotin biosynthesis clearly indicates that 
it is not simply the accumulation of a biotin free protein that is the signal for 
BioQ derepression.  
 
Biotinyl-pyruvate carboxylase is depleted more quickly than other 
biotinylated proteins during biotin deprivation  
The data presented above indicates that pyruvate carboxylase activity is 
required for to induce biotin biosynthetic genes through BioQ. As pyruvate 
carboxylase is itself a biotinylated protein, we hypothesized that loss of Pyc 
function, through loss of biotinylation, may be a sensitive indicator of cellular 
biotin starvation. To determine the effects of biotin deprivation on bacteria 
which cannot synthesize their own biotin, we used streptavidin-HRP to probe 
cellular biotinylated proteins in order to assess the kinetics of biotinylated 
protein depletion in WT, pyc::tn, and bioA::tn M. smegmatis. We identified 
biotinyl-pyruvate carboxylase (Figure 9A, top band, absent in pyc::tn, marked 
with an asterisk) as well as multiple additional biotinylated proteins. The 
pyc::tn strain lacked any gross defects in biotinylated proteins during biotin-
replete (0h) conditions (other than the absence of the ~120 kDa band for 
pyruvate carboxylase), and showed similar rates of disappearance of 
biotinylated proteins when compared to the bioA::tn strain (Figure 9A, Figure 
10). A search for homology to the Pyc biotin-binding domain within the M. 
smegmatis identified the pyruvate carboxylases MSMEG_2412 and  
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Figure 9: Analysis of protein biotinylation during biotin deprivation 
(A) Streptavidin HRP Western blot of total biotinylated protein in WT 
(MGM8007), pyc::tn (MGM8008), and bioA::tn (MGM8009) during biotin 
deprivation for 0, 3, 6, and 12 hours. Biotinylated proteins were visualized 
using streptavidin-HRP with anti-RpoB as a loading control. Pyruvate 
carboxylase (topmost band, marked with *) was absent in pyc::tn, as expected, 
but pyc::tn showed no obvious deficiencies in other biotinylated proteins. The 
biotinylated proteins used for quantitation (see Figure 10) are marked with * or 
<. (B) Quantitation of the fraction of the indicated proteins remaining at 3 
hours of biotin deprivation compared to T0 in a bioA::tn strain. Error bars are 
standard deviations of three biological replicates. 
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Figure 10: Triplicate Western blot analysis of bioA::tn for quantitation 
Western blot of total biotinylated protein in bioA::tn (MGM8009) during biotin 
deprivation for 0, 3, 6, and 12 hours. Biotinylated proteins were visualized 
using streptavidin-HRP with anti-RpoB as a loading control. 
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MSMEG_6648, as well as the acetyl/propionyl-CoA carboxylases 
MSMEG_0334, 1807, 5943, and 4716. Each of these acetyl/propionyl-CoA 
carboxylases is predicted to have a molecular weight between 60 and 75 kDa.  
The biotinylated proteins we detected with molecular weights of below 60 kDa 
do not correspond to any protein identifiable via this method, and may either 
represent degradation products or uncharacterized biotinylated proteins. 
We repeated this experiment in triplicate to assess the rate at which the biotin 
auxotroph bioA::tn loses biotinylated proteins (Figure 10), and quantitated the 
results (Figure 9B). Biotinyl-pyruvate carboxylase begins to be depleted by 
three hours of biotin depletion, a time point at which growth of biotin 
auxotrophs is comparable to WT (Figure 3C), and other biotinylated proteins 
have not yet declined in abundance. Depletion of the majority of biotinylated 
proteins is observed by six hours or more of biotin depletion, a time point that 
coincides with growth arrest of biotin auxotrophs (Figure 3E). We conclude 
that depletion of biotinyl-pyruvate carboxylase is an early marker of biotin 
deprivation and may generate the signal to upregulate biotin biosynthesis.  
 
Metabolomic analysis identifies candidate inducers of BioQ dependent 
genes 
The requirement for Pyc enzymatic function to support biotin synthesis may 
suggest that the signal for BioQ depression is a metabolic shift due to Pyc 
dysfunction.  To assess this idea, we pursued a metabolomic approach. We 
collected metabolites from WT and pyc::tn, either in biotin-replete or biotin 
depleted conditions for three hours. This short period of biotin withdrawal was 
chosen to ensure that metabolic changes were indeed a result of biotin 
deprivation, rather than generalized signals of cell death, which might occur if 
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biotin deprivation had been lengthened until growth arrest occurs. Using this 
approach, we were able to identify and to quantitate the levels of 
approximately 150 metabolites with distinct LC-MS peaks and retention times 
(Figure 11). Statistical analysis identified 16 of these metabolites present at 
levels that were significantly different between strains and/or conditions 
(Figure 12A). Pyruvate, the substrate of pyruvate carboxylase, accumulated in 
wild type cells with biotin withdrawal, consistent with the kinetics of Pyc protein 
depletion, but was depleted in all conditions in pyc::tn cells, i.e. both with and 
without biotin (Figure 12A). Principal-component analysis (PCA) on the 
metabolomic data (Figure 12B) separates the samples primarily by strain on 
the first principal component, which explains the majority of the variation 
between samples. The PCA also shows that biotin withdrawal from the wild 
type strain causes a metabolic shift in both principal components, whereas 
biotin withdrawal from pyc::tn has a minimal effect (Figure 12B)  Additionally, 
the majority of the differences between metabolites which differed between the 
strains (Figure 12A) or metabolites as a whole (Figure 11) are found between 
strains, rather than between conditions. These metabolomic data indicate that 
biotin withdrawal from wild type cells causes broad metabolic perturbation, 
including dysfunction of Pyc. In cells lacking Pyc, these metabolic changes are 
blunted or absent and the strain, even with biotin, has adapted to the loss of 
Pyc.  
We performed pathway analysis (Kamburov et al. 2011) and identified 
alanine/aspartic acid/glutamic acid metabolism, arginine biosynthesis, lysine 
biosynthesis, the citric acid cycle, and pyruvate metabolism to be 
overrepresented within our list of significantly perturbed metabolites. However, 
we were unable to restore growth of pyc::tn on medium lacking biotin by   
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Figure 11 : All metabolites identified from analysis of pyc::tn. 
We collected metabolites from three replicates of WT (MGM8007) and pyc::tn 
(MGM8008) after three hours of growth with or without biotin. Metabolite levels 
were normalized to total biomass measured in each replicate using a 
generalized linear regression model. All metabolites with identifiable signal in 
each replicate are summarized here. . Higher abundance for a metabolite than 
expected by the model given the strain’s biomass is indicated in red and lower 
abundance in green. 
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Figure 12: Significantly perturbed metabolites in pyc::tn 
(A) We collected metabolites from three replicates of WT (MGM8007) and 
pyc::tn (MGM8008) after three hours of growth with or without biotin. 
Metabolite levels were normalized to total biomass measured in each replicate 
using a generalized linear regression model. Metabolites which were 
significantly different between strains or conditions are summarized in the heat 
map. Higher abundance for a metabolite than expected by the model given the 
strain’s biomass is indicated in red, and lower abundance in green. (B) 
Principal-component analysis (PCA) of all metabolites. Each dot is one 
replicate of the indicated strain/biotin condition. 
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supplementing the media with metabolites found at lower levels in pyc::tn than 
in WT (data not shown), possibly because these metabolites are not cell-
permeable. It is also possible that the factor required to derepress biotin 
synthesis is a modified species of one of the accumulated metabolites or that 
our method failed to detect the relevant metabolite.  
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CHAPTER THREE: ΔRIP1 M. TUBERCULOSIS IS SENSITIVE TO 
MULTIPLE TYPES OF STRESS 
 
Response of Δrip1 to in vitro models of stress 
To determine which stresses are responsible for the virulence defect of Δrip1, 
we assessed its sensitivity using various previously-described in vitro models 
of host-mediated stress. We first cultured WT, Δrip1, and complemented 
strains of M. tuberculosis in the presence of lysozyme (as a representative of 
antimicrobial peptides) (Kanetsuna 1980, Nawrocki, Crispell, and McBride 
2014), the detergent SDS (Banaei et al. 2009, Vandal et al. 2009), low pH 
(Vandal et al. 2009, Schaible et al. 1998), hydrogen peroxide (Voskuil et al. 
2011, Springer et al. 2001), and the nitric oxide donor DETA-NO (Idh et al. 
2012, Voskuil et al. 2011). For each of these stresses, Δrip1 was killed at 
approximately the same frequency as WT except in the case of nitric oxide, 
which killed approximately 90% of Δrip1 bacilli at a dose which did not have an 
effect on the survival of WT (Figure 13A-E).  
To ensure that this phenotype was not specific to the dose of stress used, we 
determined the minimum inhibitory concentration (MIC) of each stress for WT, 
Δrip1, and the complemented strain. As before, Δrip1 showed increased 
sensitivity to DETA-NO, with an eight-fold lower MIC in Δrip1 compared to WT, 
though we only saw partial complementation (Figure 13F). Conversely, each 
of these strains had identical MICs when treated with the other stresses we 
had previously tested, confirming that Δrip1 is not attenuated in its response to 
these stresses. 
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Figure 13: Δrip1 is attenuated in models of nitrosative stress, hypoxia, 
and when treated with various antibiotics. 
(A-E) Δrip1 is attenuated when treated with DETA-NO. CFUs were measured 
when WT + pEV (MGM345), Δrip1 + pEV (MGM349), and Δrip1 + pRip1 
(MGM350) M. tb were exposed to various stresses.  (A) 10 mM hydrogen 
peroxide, 4h exposure. (B) 2.5 mg/mL lysozyme, 2h (C) 0.05% SDS, 2h (D) 
acidified medium, pH 4.5, 7 d (E) 200 µM DETA-NO added daily, 3d. (F) 
Minimum inhibitory concentration (MIC) was measured for WT + pEV, Δrip1 + 
pEV, and Δrip1 + pRip1. Triplicate biological replicates were measured. (G) 
Δrip1 is not sensitive to gross nutrient starvation. WT + pEV, Δrip1 + pEV, and 
Δrip1 + pRip1 were incubated without shaking in PBS, and persistence was 
measured by CFU.  (H) Δrip1 is attenuated in the Wayne model. WT + pEV, 
Δrip1 + pEV, and Δrip1 + pRip1 were tested in the Wayne model of hypoxia, 
growth and persistence was measured by CFU. (I) Δrip1 is effectively killed by 
multiple antibiotics. WT + pEV, Δrip1 + pEV, and Δrip1 + pRip1 were 
incubated with 40 µg/mL vancomycin, 0.1 µg/mL isoniazid, 4 µg/mL 
streptomycin, 0.2 µg/mL rifampicin, or no antibiotic control, and CFUs were 
measured at the end of 1 week.  CFU counts represent a triplicate of biological 
replicates; error bars represent standard deviation. 
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In addition to active means of killing, the host also attempts to suppress 
growth of M. tuberculosis by limiting its access to nutrients and to oxygen. To 
test whether Δrip1 is able to survive under these conditions, we utilized the  
Loebel model of PBS starvation (Gengenbacher et al. 2010, Loebel, Shorr, 
and Richardson 1933, Dietrich et al. 2015) and the Wayne model of hypoxia 
(Wayne and Sohaskey 2001, Wayne and Hayes 1996). Over two weeks of 
culture in PBS, Δrip1 experienced a minor drop in culturable bacilli comparable 
to WT and complemented strains (Figure 13G), indicating resistance to 
nutrient starvation. However, Δrip1 showed an attenuated phenotype in both 
early (0-7 days) and late (14-21 days) stages of hypoxia (Figure 13H).  
The sensitivity of Δrip1 to both nitric oxide and hypoxia may indicate a general 
susceptibility to redox stress, though Δrip1 is not sensitive to hydrogen 
peroxide. Recent work has indicated that otherwise disparate classes of 
antibiotics may act via a common mechanism of inducing oxidative stress 
(Kohanski et al. 2007) and that the cellular response to antibiotics and to 
oxidative stress may be similar (Idh et al. 2012, Bulatovic et al. 2002, 
Nandakumar, Nathan, and Rhee 2014). We cultured WT, Δrip1, and 
complemented strains in the presence of one of four antibiotics: vancomycin, 
isoniazid, rifampicin, and streptomycin. Δrip1 was effectively killed by each of 
these antibiotics, while WT M. tb was less susceptible. 
 
Role of proteolysis, protein-binding PDZ domain, and σ factors in Δrip1 
response to stress 
Since identifying Rip1 as an important factor in M. tb virulence, the Glickman 
lab has attempted to elucidate the mechanism of this site-2 protease. Studies 
have identified the cognate anti-sigma factors for σ K, L, M (Sklar et al. 2010) 
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and D (Schneider, Sklar, and Glickman 2014) as substrates of Rip1. Rip1 
cleaves these transmembrane anti-sigma factors, de-tethering their respective 
sigma factors from the cell membrane and allowing them to drive transcription 
of their regulons. In completing these studies, members of the Glickman lab 
constructed a catalytically-dead (Rip1H21A) Rip1 (Sklar et al. 2010) and a 
truncated Rip1 lacking its regulatory PDZ domain (Rip1ΔPDZ) (Schneider et 
al. 2013). To explore the mechanism of Δrip1 sensitivity to the previously-
identified stresses, we expanded our assays to include Rip1H21A, Rip1ΔPDZ, 
the triple mutant ΔσKLM, and the mutant ΔσD. 
A repeat of the previous experiment in which M. tb was cultured for three days 
in the presence of DETA-NO confirmed our prior finding that Δrip1 is highly 
sensitive to nitrosative stress. Δrip1 was killed at a frequency of 90% or 
greater at doses for which WT and the complemented strain were not killed ( 
Figure 14A, doses > 31.25 µM; previous experiment used 200 µM). Both the 
ΔσKLM, and ΔσD mutants were resistant to DETA-NO treatment, in 
concordance with the lack of in vivo attenuation found for these strains (Sklar 
and Glickman, unpublished data). Conversely, both the Rip1ΔPDZ and 
Rip1H21A constructs failed to complement the Δrip1 mutant, with expression 
of the H21A protein conferring even further sensitivity. The hyper-attenuation 
of the H21A-expressing strain confirms that Rip1 proteolytic activity is required 
to maintain resistance to DETA-NO. Additionally, the attenuation of the 
Rip1ΔPDZ-expressing mutant demonstrates that the protein-adaptor or 
regulatory activity of the PDZ domain is also necessary. We have been unable 
to construct a ΔσKLMD quadruple mutant to absolutely confirm that these sigma 
factors do not act in a redundant manner, but it seems likely that there are  
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Figure 14: Contribution of catalytic activity, PDZ domain, and sigma-
factors to Δrip1 attenuation. 
WT + pEV (MGM309), Δrip1 + pEV (MGM349), Δrip1 + pRip1 (MGM350), 
Δrip1 + pRip1H21A (MGM573), Δrip1 + pRip1ΔPDZ (MGM575), ΔσKLM, + pEV 
(MGM8052), and ΔσD + pEV (MGM8053) were tested when treated with 
DETA-NO, in the Wayne model, and when treated with antibiotics. (A) 
Expression of Rip1H21A hyperattenuates Δrip1 in response to DETA-NO; the 
PDZ domain of Rip1 is required for resistance. The above strains were treated 
with DETA-NO at varying concentrations for three days, with DETA-NO being 
refreshed daily. CFUs were measured at the end of the experiment, and 
survival was measured as the fraction of CFUs at each concentration of 
DETA-NO normalized to CFUs for the no treatment control. (B) Catalytic 
activity of Rip1 is dispensable in the Wayne model; the PDZ domain of Rip1 is 
required for full resistance. The above strains were tested in the Wayne 
model, and CFUs were measured at various points. (C) Catalytic activity of 
Rip1 and its PDZ domain are required for resistance to antibiotics. MICs were 
measured for he above strains for isoniazid, rifampicin, streptomycin, and 
vancomycin. Measurements were taken in triplicate. CFUs for this figure 
represent the average of three biological replicates; error bars indicate 
standard deviation. 
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unidentified Rip1 substrates which play a role in the Rip1-mediated response 
to nitrosative stress. 
Addition of these strains to our Wayne model experiments did not show the 
same biochemical and genetic relationships between phenotypes (Figure 
14B). Strikingly, while the Rip1ΔPDZ-expressing strain did show a slightly 
milder attenuation (compared to Δrip1 with an empty vector) in response to 
hypoxia, expression of Rip1H21A fully complemented the Δrip1 strain. This 
result demonstrates that the catalytic activity of the Rip1 protease is not 
required for resistance to hypoxia. Proteolysis by any enzyme may not be 
necessary; alternatively, expression of Rip1H21A may permit another 
protease to form a protein-protein complex with Rip1 and to function in the 
absence of Rip1 proteolysis. ΔσKLM M. tb possessed a mild phenotype, 
suggesting that one or more of their anti-sigma factors are relevant Rip1 
substrates in the context of hypoxia, while ΔσD was not attenuated.  
We performed MIC assays for each of the four antibiotics tested above on 
these strains, and found that results tended to segregate as they did in tests of 
DETA-NO, sensitivity, though this was not true for all of the antibiotics ( 
Figure 14C, comparison of all phenotypes in Table 2). Expression of 
Rip1H21A conferred hypersensitivity in the case of streptomycin and 
rifampicin, while it had failed to complement Δrip1 in the case of isoniazid and 
vancomycin.   
Expression of Rip1ΔPDZ partially complemented Δrip1 for rifampicin 
sensitivity, but did not complement Δrip1 for sensitivity to isoniazid, 
streptomycin, or vancomycin. Both ΔσKLM and ΔσD were resistant to rifampicin 
and streptomycin, sensitive to isoniazid, and had a moderate phenotype when 
exposed to vancomycin. 
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Table 2: Summary of Δrip1 phenotypes 
Sensitivity in the Wayne model, to DETA-NO, and to antibiotics are 
summarized. Resistant indicates WT phenotype, sensitive indicates Δrip1 
phenotype, hypersensitive indicates a more attenuated phenotype than Δrip1, 
and partial indicates a phenotype between WT and Δrip1. 
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We then wished to investigate whether these phenotypes illuminated novel 
interactors with Rip1. DosR is a response regulator which is phosphorylated 
by its two sensor kinases DosS/T in response to hypoxia, NO, or CO (Kumar 
et al. 2007). The DosR regulon has been extensively characterized (Voskuil et 
al. 2003, Voskuil et al. 2011), and DosR has been shown to be important in 
the response to hypoxia and to NO (Leistikow et al. 2010, Voskuil et al. 2011), 
though the extent to which it is essential is controversial (Rustad et al. 2008).  
 
Role of DosR, Rv2625c, and NaHS-reversible oxidative stress in Δrip1 
sensitivity to stress 
To test whether Δrip1 is able to induce the DosR regulon, we treated WT and 
Δrip1 M. tb with DETA-NO. Both WT and Δrip1 strongly induced DosR regulon 
genes hspX, Rv2625c, and dosR itself, indicating no defect in the Δrip1 strain 
for this response (Figure 15A). Neither strain induced clpP1 transcription, as 
would be expected for a hypoxia-response gene which is not regulated by 
DosR (McGillivray, Golden, and Kaushal 2015).  These remaining hypoxia- 
induced genes as well as the genes of the enduring hypoxia response (Rustad 
et al. 2008) remain to be tested. Rv2625c, which is induced during hypoxia 
and is part of the DosR regulon, is also annotated as a site-2 protease, though 
unlike Rip1, deletion of the gene encoding Rv2625c does not confer a growth 
defect (Makinoshima and Glickman 2005). As catalytic activity of Rip1 is 
inessential during the Wayne model, we hypothesized that Rv2625c may be 
acting as a protease either in parallel to Rip1 or in its stead. To test this 
hypothesis, we deleted rip1 in the ΔRv2625c background (confirmed by 
Southern blot, Figure 15B). We then tested ΔRv2625c and the 
ΔRv2625c/Δrip1 double mutant in the Wayne model. ΔRv2625c grew and   
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Figure 15: Genetic interactors in Δrip1 sensitivity to stress and reversion 
of stresses with NaHS 
(A) Δrip1is able to induce the DosR regulon in response to NO. WT (MGM345) 
and Δrip1 (MGM349) M. tb were treated with NO or not treated as a control, 
and then RT-qPCR was performed to measure induction of DosR regulon 
genes (hspX, Rv2625c, dosR). clpP1 transcript was used as a negative 
control. (B) Deletion of Rv2625c in the Δrip1 background. Rv2625c was 
deleted by specialized phage transduction, and the deletion was confirmed by 
Southern blot. rip1 deletion was confirmed (left) in the double mutant, and 
Rv2625c deletion was confirmed in the ΔRv2625c single mutant control 
(MGM705) and double mutant, double mutant. (C) Deletion of Rv2625c 
confers no additional sensitivity in the Wayne model. Δrip1/Rv2625c + pEV 
(MGM8051) was tested for growth and persistence in the Wayne model. CFUs 
are the average of three biological replicates; error bars indicate standard 
deviation. (D-F) MICs were tested for WT + pEV, Δrip1 + pEV, and Δrip1 + 
pRip1 (MGM350) when treated with various stresses with no additional 
treatment and when 100 µM NaHS was added to counteract oxidative stress. 
(D) Δrip1 shows no sensitivity to diamide, and NaHS shows little effect. (E) 
NaHS does not reverse Δrip1 sensitivity to DETA-NO, but does improve 
resistance of WT and Δrip1 + pRip1. (F) NaHS reverses the sensitivity of Δrip1 
to isoniazid, rifampicin, streptomycin, and vancomycin. 
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persisted during hypoxia at a WT level, while the ΔRv2625c/Δrip1 mutant 
phenocopied Δrip1 but conferred no additional defect (Figure 15C). As such, 
we concluded that Rv2625c does not act as either an additional or a backup 
protease along with Rip1 during the response to hypoxia. 
A recent study identified Rip1 as a genetic interactor with the P-type ATPase 
CtpC, which responds to oxidative stress (Nambi et al. 2015). This study found 
that the effects of oxidative stresses like DETA-NO, or the thiol-specific 
oxidant diamide could be reversed with the addition of the reducing agent 
NaHS. Additionally, a prior study found that addition of a different reducing 
agent, thiourea, could reverse antibiotic-mediated killing of strains sensitive to 
oxidative stress (Nandakumar, Nathan, and Rhee 2014). We therefore tested 
the effects of NaHS during treatment with diamide, DETA-NO, and antibiotics. 
NaHS did increase resistance of WT, Δrip1, and the complemented strain to 
diamide, but Δrip1 did not show more sensitivity to diamide than WT M. tb, 
indicating that the defect of Δrip1 is likely not in thiol homeostasis (Figure 
15D).  
Puzzlingly, addition of NaHS to media during DETA-NO treatment showed a 
stronger effect on WT and the complemented strain than it did on Δrip1 
(Figure 15D). As such, we concluded that the Δrip1 defect in response to 
DETA-NO is not reversible by NaHS, which may indicate the presence of 
targets of NO which cannot be acted upon by NaHS, though they may be 
amenable to other reducing agents. Addition of NaHS during antibiotic 
treatment successfully increased resistance of Δrip1 to all four antibiotics, 
though it was only occasionally successful at reversing the effect of antibiotics 
in WT and in the complemented strain. Thus, it seems likely that Δrip1 
sensitivity to antibiotics is mediated by oxidative stress, though we are unable 
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to determine whether this sensitivity is a result of greater oxidative stress at 
the baseline state or because of an inability to respond to oxidative stress 
when it occurs.  
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CHAPTER FOUR: ΔRIP1 M. TUBERCULOSIS IN NOS2-/- MICE 
 
Δrip1 attenuation in vivo is partially attributable to nitric oxide 
Based on the finding that Δrip1 M. tb are susceptible to DETA-NO treatment 
(Figure 13E-F), we decided to investigate the contribution of nitric oxide to the 
in vivo phenotype of Δrip1. Δrip1 is highly attenuated in the mouse model of 
infection (Sklar et al. 2010) in both the acute and chronic phases of infection, 
and is eventually cleared completely from the mouse.  
The iNOS (inducible nitric oxide synthase) knockout mouse (nos2-/-) is 
commercially available and has been used in numerous studies to determine 
the contribution of nitric oxide to host immunity to M. tb infection via infection 
of the mouse (MacMicking et al. 1997, Cooper et al. 2000, Scanga et al. 2001) 
or of macrophages derived from the iNOS knockout mice (Hu and Coates 
2011, 2009). More recent work (Beisiegel et al. 2009, Mishra et al. 2017) has 
attempted to distinguish between the cytotoxic and immunomodulatory 
activities of nitric oxide. 
We infected iNOS knockout mice with WT and Δrip1 and measured bacterial 
load in the lungs (Figure 16A) and spleen (Figure 16B) as well as survival of 
the mice over time (Figure 16C). As has been previously observed (Scanga et 
al. 2001), iNOS knockout mice infected with WT M. tb rapidly succumb to the 
infection in around 30 days. In comparison, Δrip1-infected iNOS knockout 
mice began to experience lethal complications from the infection at around 70 
days, and by the conclusion of the experiment (day 112), only half of the 
infected mice had died. 
In comparison to previous experiments (Figure 16A-B, dotted lines), in which 
we infected WT C57Bl/6 mice with WT and Δrip1 M. tb, infection of the iNOS   
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Figure 16: Δrip1 regains most but not all of its virulence when infecting 
iNOS knockout mice 
(A-C) Infection of iNOS knockout mice with Δrip1 (MGM3206) and WT (EF2) 
(solid lines). Data from a prior infection of Bl/6 mice is superimposed (dotted 
lines). (A) Bacterial burden in the lungs. (B) Bacterial burden in the spleen. (C) 
Survival rate of 10 mice per strain. (D-E) Subsequent infection of iNOS 
knockout and Bl/6 mice with Δrip1. (D) Bacterial burden in the lungs. (E) 
Bacterial burden in the spleen. CFU counts are the average of four biological 
replicates per organ. Error bars indicate standard deviation. 
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knockout mice showed no difference before week 1. Between weeks 1 and 3, 
Δrip1 showed no defect compared to WT in the iNOS knockout mouse, while 
in Bl/6 mice, the virulence defect between WT and Δrip1 increased over this 
time period. After this time point, iNOS knockout mice established some 
control over the infection, albeit with a very high bacterial load (107-108 
CFU/lung or spleen) which exceeded that in a chronic infection of Bl/6 mice 
with WT M. tb. It is also important to note that measures of bacterial burden 
taken at the late time points (d71 and 112) are necessarily from the fraction of 
mice which have established the best control over the infection, as the most-
affected mice were dying or had died by these time points. 
Because this infection was carried out with a high inoculum (~200-250 
CFU/lung, compared to 100 CFU/lung typical of prior experiments), we 
decided to repeat the experiment to ensure that the result we found was not 
merely inoculum-dependent. To do this, we infected Bl/6 and iNOS knockout 
mice with Δrip1 (Figure 16D-E). In this experiment, we obtained a lower 
inoculum (~50 CFU/lung) which resulted in better host control of the infection 
as demonstrated by lower bacterial burden (Figure 16D-E) and no mortality. In 
comparison to the prior experiment, we found a smaller, though still significant 
difference between infection of Bl/6 and iNOS knockout mice with Δrip1 of 
about 1-2 logs in the lung and 1 log in the spleen. The restoration of virulence 
of Δrip1 in iNOS mice thus partially accounts for the defect of Δrip1 compared 
to WT M. tb in infection of Bl/6 mice (2-3 logs in the lung, 1-2 logs in the 
spleen) (Figure 16A-B, dotted lines). As such, we concluded that the defect of 
Δrip1 can be partially but not fully attributed to its sensitivity to nitric oxide. Its 
very early defect from the time of inoculation to week 1 is entirely independent 
of nitric oxide, as expected, since it comes before the induction of adaptive 
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immunity. Both this initial defect and the nitric oxide-independent defect Δrip1 
shows (~1 log) after week 1 remain to be explored. 
 
iNOS knockout mice infected with Δrip1 develop histopathologic 
features of granulomas 
To further characterize the phenotype of the Δrip1 mutant in iNOS knockout 
mice, we performed histology on fixed lung sections from each infection. 
Hematoxylin and eosin (H&E) staining of lung sections from day 21 of the 
infection (Figure 17A-B) demonstrates that infection of iNOS knockout mice 
with WT M. tb (Figure 17A) yields a significant inflammatory infiltrate, with 
approximately 50% of the lung tissue involved, while infection of the same 
mouse strain with Δrip1 (Figure 17B) yields a more mild phenotype, with 
distinct sites of inflammation. These data are in accordance with the bacterial 
loads found in the two infections. By day 71, the Δrip1 infection has reached 
nearly the same bacterial load as the WT infection at day 21 (Figure 16A), and 
the pathology of the Δrip1-infected mouse has similarly expanded to include a 
large percentage of the lung (Figure 17C). Intriguingly, this pathology includes 
both disorganized inflammatory infiltrates as seen in the day 21 time point as 
well as the beginning of more localized infiltrates. At day 112, (Figure 17D), 
large localized infiltrates are clearly visible, with many displaying an acellular 
center indicative of necrosis. Infiltrates are surrounded by a poorly-stained 
region which may represent foamy macrophages (Russell et al. 2009) which 
typically are found at the interface of necrotic regions and the surrounding lung 
and would be washed away during deparaffinization. 
As these localized lesions appeared to share similar features with human 
granulomas, we decided to perform additional histological stains to further  
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Figure 17: Progression of pathology in WT and Δrip1 infected iNOS 
knockout mice 
H&E staining of formalin-fixed, paraffin-embedded lung sections from WT (A) 
and Δrip1-infected (B-D) iNOS knockout mice. (A-B) Day 21. (C) Day 71. (D) 
Day 112. WT-infected mice have diffuse inflammatory infiltrates at day 21, 
while Δrip1-infected mice develop localized inflammatory infiltrates from day 
71 to day 112. Signs of necrosis develop by day 112. 
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characterize their pathology (Figure 18). Granulomas are typically surrounded 
by fibrotic tissue in both human (Solsona Peiro, de Souza Galvao, and Altet 
Gomez 2014) and non-mouse animal models (Subbian et al. 2011) of 
tuberculosis infection. Masson’s trichrome staining (Figure 18B-C) indicated 
limited fibrotic tissue (blue staining) in the border between the inflammatory 
infiltrate of WT-infected mice at day 21 (Figure 18B), but a fibrotic sheath 
forming around the granuloma of a Δrip1-infected mouse at day 112 (Figure 
18C; compare to H&E staining of the same lesion Figure 18A).  
Additionally, we used acid-fast staining to examine the localization of M. tb 
bacilli in the lung during the infection (Figure 18D). Bacteria were largely 
localized inside the granulomas, with a smaller fraction of bacteria present at 
non-granulomatous sites of inflammation. As has been seen previously (Hoff 
et al. 2011), bacilli were present both in the cellular and acellular/necrotic 
areas of the granuloma. Bacilli were most common in the unstained area 
directly inside the fibrotic sheath which indicates foamy macrophages, but 
could also be found in the necrotic center of granulomas. Bacteria were 
present, but less common, in areas of the granuloma which contained cellular 
infiltrates, and were also less common in cellular, non-necrotic granulomas. 
To assess the types of immune cells present in the inflammatory infiltrates we 
saw, we utilized fluorescent immunohistochemistry to stain for CD11b 
(macrophages/monocytes) and CD3 (T cells) (Figure 19). CD11b staining was 
highly evident in all samples appeared to match much of the staining of 
inflammatory infiltrates as seen with H&E (Figure 17), especially at early time 
points (Figure 19A-B). CD3 staining was far less common, with individual 
CD3+ cells being evident in non-granulomatous tissue. Some, but not all 
necrotizing granulomas were characterized by a ring of CD3+ cells at the  
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Figure 18: Comparison of H&E, Masson’s trichrome, and acid-fast 
bacillus staining in granulomatous lesions. 
(A) H&E staining of a necrotic granuloma (further zoom of lesion from Figure 
17D, indicating the fibrotic, unstained, cellular, and necrotic areas of the 
lesion. (B-C) Masson’s trichrome staining of (B) an inflammatory infiltrate from 
a WT-infected mouse at day 21 (further zoom of lesion from Figure 17A) and 
(C) the granuloma pictured in part A. Cytoplasm is stained red, and fibrotic 
tissue is stained blue. (D) Acid-fast bacillus staining of the granuloma from part 
A. Acid-fast bacilli are stained red, other tissues are stained blue. All images 
measured at 10x magnification. 
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Figure 19: Fluorescent immunohistochemistry of lung sections to detect 
CD3+ and CD11b+ cell infiltrates. 
(A) Staining of WT-infected iNOS knockout mouse lung section harvested at 
day 21. (B) Δrip1-infected iNOS knockout mouse lung section harvested at 
day 21. (C) day 71 (D) day 112. Images correspond to those taken of H&E 
staining in Figure 17. DAPI (cell nuclei) stained in blue, CD3 (T cells) stained 
in red, CD11b (macrophages and monocytes) stained in green. 
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periphery of the granuloma (Figure 19D). Additionally, certain cellular 
granulomas did show CD3+ cell infiltrates, though it is uncertain whether this is 
nonspecific staining, as some acellular regions and the outsides of lung 
sections also tended to stain as CD3+. 
Staining of Δrip1-infected iNOS knockout mice was comparable to staining of 
WT-infected mice at the day 21 time point. WT-infected mice showed stronger  
staining for CD11b, but it is difficult to distinguish whether this is because of 
the differences between strains or merely because of the higher bacterial 
burden seen in WT-infected mice (Figure 17A). 
Hypoxia is a relevant stress involved in the control of M. tb during infection 
(Rao et al. 2008, Rustad et al. 2009), but while human granulomas and non- 
mouse animal models of M. tb infection produce  hypoxic lesions (Rustad et al. 
2009, Via et al. 2008), this is not typically the case in infection of mice (Aly et 
al. 2006). Recently, the C3HeB/FeJ (“Kramnik”) mouse model, which 
recapitulates multiple phenotypes of granulomas, has been shown to yield 
hypoxic lesions (Driver et al. 2012, Harper et al. 2012). As the lesions we saw 
in infection of iNOS knockout mice with Δrip1 were also granuloma-like, we 
decided to test these lesions for hypoxia. 
Pimonidazole forms adducts with proteins in the presence of hypoxia, and has 
been used widely in immunohistochemistry both in the study of tuberculosis 
(Harper et al. 2012, Via et al. 2008) as well as in the study of tumor hypoxia 
(Varia et al. 1998). During our second infection (Figure 16D-E), we injected a 
subset of mice with pimonidazole prior to sacrifice, and then examined lesions 
found at late time points (day 91-135). Positive staining for pimonidazole was 
highly evident in both cellular (Figure 20A-B) and necrotic (Figure 20C) 
lesions. Unaffected parts of the lung did not show positive staining  
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Figure 20: Pimonidazole staining for hypoxia in granulomatous lesions 
Mice were injected with pimonidazole prior to sacrifice, and sections were 
stained using an anti-pimonidazole adduct antibody. H&E stained lesions are 
shown on the left, corresponding pimonidazole staining is on the right. (A) 5x 
magnification image of a cellular lesion, showing affected and unaffected 
tissue. (day 135) (B) 10x magnification image of the same lesion (C) 10x 
magnification image of a necrotic lesion (day 135) (D) 10x magnification image 
of a necrotic lesion from a mouse not infected with pimonidazole prior to 
sacrifice (day 91) (E) Comparison of bacterial burden at day 91 from mice 
injected or not injected with pimonidazole prior to harvest. No change in CFU 
is apparent. Pimonidazole-injected groups are the average CFUs from 3 mice 
each, non-pimonidazole-injected groups are the average CFUs from 4 mice 
each. Error bars indicate standard deviation. 
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(Figure 20A, bottom left area). Some nonspecific staining is likely to be 
present, as areas peripheral to the granuloma with strong inflammatory 
infiltrates also stained positive for pimonidazole (Figure 20B-C), which is not 
the case in rabbit granulomas (Datta et al. 2016), though this may also be a 
result of differences between the animal models. Lesions from mice not 
injected with pimonidazole did not show the same intensity of staining, though 
some light-brown color can be seen (Figure 20D). Finally, we assessed 
evident bacterial burden in mice injected or not injected with pimonidazole 
(Figure 20E). At both early time points (day 23, data not shown) and at time 
points at which hypoxia was evident (Figure 20E, day 91), both Bl/6 and iNOS 
mice show no change in apparent CFU when pimonidazole was injected into 
the host before harvest. Therefore, future experiments will not necessitate a 
large number of mice not be injected with pimonidazole to be used for CFU 
counts, and we should be able to analyze larger numbers of lesions for 
hypoxia. 
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DISCUSSION 
 
Pyruvate carboxylase catalytic activity is required for BioQ-mediated 
derepression of biotin biosynthesis under low-biotin conditions* 
We have uncovered an unanticipated role for pyruvate carboxylase in 
regulating biotin biosynthesis in mycobacteria. We identified transposon 
insertions in MSmeg_2412, encoding pyruvate carboxylase, as unable to grow 
on medium lacking biotin. The role of pyruvate carboxylase in regulating biotin 
biosynthesis is to mediate transcriptional induction of BioQ repressed biotin 
biosynthetic genes. In the absence of Pyc, these genes remain repressed, 
conferring biotin auxotrophy. This function of Pyc in biotin biosynthesis 
requires the active site residues of the Pyc enzyme as well as enzyme 
biotinylation, strongly suggesting that the participation of Pyc in the biotin 
pathway reflects its canonical enzymatic activity in central metabolism. We find 
that biotinyl-Pyc is the most rapidly depleted biotinylated protein upon biotin 
withdrawal, supporting the idea that the loss of Pyc activity is an early 
consequence of biotin starvation.  Our primary model to explain these findings 
is that transient loss of pyruvate carboxylase activity caused by biotin 
deprivation generates the metabolic signal that derepresses BioQ-regulated 
genes. This metabolite could be the direct substrate of Pyc, pyruvate, which 
we find to accumulate with biotin withdrawal in our metabolomic studies. 
However, it may be unlikely that such a central metabolite, the levels of which 
could be affected by many factors independent of biotin starvation, would be 
the signal for BioQ depression. More likely is that the BioQ signal is Pyc 
dependent, but is a downstream conversion product of a metabolite that 
                                                          
* This section is derived from: Lazar et al 2017 (in review) 
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accumulates due to Pyc dysfunction, which we did not identify in our 
metabolomic studies. Further work is therefore required to identify the Pyc 
dependent BioQ inducer.  
At first glance, it may seem paradoxical that transient loss of Pyc activity 
(through loss of biotinylation during biotin deprivation) induces biotin 
biosynthesis through BioQ, whereas permanent loss (i.e. genetic deletion) 
prevents BioQ derepression. Our data indicate that the Pyc enzyme, itself a 
biotinylated protein, declines rapidly in abundance during the early hours of 
biotin withdrawal in a strain that cannot synthesize biotin, before other 
biotinylated proteins have declined and before cell death occurs. Changes in 
metabolites caused by the transition of pyruvate carboxylase from holo- to 
apo- form, and its subsequent loss of catalytic activity, would be predicted to 
result in acute metabolic shifts that would be different from those experienced 
by a strain lacking pyruvate carboxylase through genetic deletion. Indeed, our 
metabolomic analysis strongly supports that 1) biotin withdrawal causes broad 
metabolic shifts in wild type cells 2) these shifts are much less dramatic or 
absent in Pyc deficient cells and 3) genetic deletion of pyc causes metabolic 
perturbation even in the presence of biotin such that this mutant has adapted 
to the metabolic shifts that accompany acute loss of Pyc function. This effect is 
obvious when observing the detected levels of pyruvate, the substrate of Pyc. 
Pyruvate accumulates in wild type cells upon biotin starvation, consistent with 
Pyc dysfunction. However pyruvate does not accumulate in the Pyc deficient 
strain in any condition, indicating that the strain has adapted to chronic loss of 
pyruvate carboxylase.  
An alternative explanation for the role of pyruvate carboxylase in regulation of 
biotin biosynthesis would be that BioQ senses low levels of biotin in a manner 
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similar to E. coli BirA. When biotin levels are low, biotin-binding domains would 
not be saturated with biotin cofactor, and unbiotinylated BCCP domains could 
interact directly with BioQ to modulate BioQ’s regulatory function. However, 
this hypothesis is unlikely to explain the mechanism by which Pyc relives 
BioQ-mediated repression. Expression of mutant pyruvate carboxylase 
enzyme lacking the biotin attachment lysine (K1093), and which we have 
shown is not biotinylated, is unable to restore biotin prototrophy to pyc::tn. As 
this Pyc enzyme accumulates in its unbiotinylated form, it should directly 
depress BioQ if the accumulation of biotin free Pyc were the signal, yet it is 
unable to complement the auxotrophy.  Additionally, this mechanism would be 
atypical of TetR like repressors, which typically bind a small molecule rather 
than a protein as their ligand, though proteins have been shown to serve as 
the ligands of TetR like repressors in certain cases (Burkovski 2007). 
A surprising finding of our study is that a Pyc allele lacking the N terminal 
biotin carboxylase domain (BC) is able to support biotin biosynthesis, yet an 
amino acid substitution in the BC domain active site (E288K) cannot. Our 
original suspicion that this effect was due to the N terminal BC fragment  that 
may be expressed in the pyc::tn strain is belied by the ability of Pyc∆BC to 
complement the ∆pyc strain (in which the entire pyc ORF is deleted). We 
hypothesize that complementation with the CT+BCCP truncation may occur 
with the biotin carboxylase domain of another biotin-utilizing enzyme in trans, 
such as the acetyl/propionyl-CoA carboxylase alpha chain enzymes 
MSMEG_0334 or MSMEG_1807. Each of these proteins contains a BC and 
BCCP domain, but lacks a CT domain, which is present in the beta chain 
present on a separate polypeptide. In the E288K Pyc mutant, the presence of 
structurally intact but inactive BC domain in the Pyc tetramer may prevent this 
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in trans complementation. Prior work has demonstrated that Pyc truncations 
retain their enzymatic activity when alone (Sueda, Islam, and Kondo 2004) 
and intermediate transfer between domains has been shown to occur (St 
Maurice et al. 2007, Islam, Sueda, and Kondo 2005). However, full 
explanation of this finding will require further biochemical characterization of 
the mycobacterial Pyc enzyme.  
In summary, we have uncovered a new mechanism of biotin regulation, which 
relies on the competence of a biotinylated enzyme of central metabolism as a 
sensor for biotin sufficiency. We anticipate that this mechanism may be 
applicable to other bacteria which have dissociated biotin ligase function from 
transcriptional regulation of biotin biosynthesis.  
 
Δrip1 is sensitive to nitric oxide, hypoxia, and multiple antibiotics 
We have identified nitric oxide and hypoxia as relevant host-mediated stresses 
which are likely to play a role in its in vivo phenotype. As both of these 
stresses are redox-related, we also tested Δrip1 for sensitivity to antibiotics 
and determined that Δrip1 is sensitive to multiple antibiotics with diverse 
biological targets and chemical makeup, which lends credence to the idea that 
there may be a single or small number of shared mechanisms which explain 
these sensitivities. However, Δrip1 was neither sensitive to hydrogen peroxide 
nor diamide, two different sources of oxidative and thiol homeostatic stress, 
which indicates that it is not grossly sensitive to all sources of redox stress. As 
Rip1 is a membrane protein and Δrip1 has been shown (Makinoshima and 
Glickman 2005) to have perturbations in its cell wall, changes in permeability 
may be responsible for some or all of these phenotypes; similarly, changes in 
efflux may also explain the pleiotropic phenotype of the Δrip1 mutant. 
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However, it seems somewhat unlikely that such a broad mechanism could 
account not only for the attenuation we saw but also fail to yield sensitivity to 
hydrogen peroxide, acid, or other mechanisms we were unable to demonstrate 
effectively killed Δrip1. We could test Δrip1 for uptake of ethidium bromide 
(Rodrigues et al. 2013) or fluorescently-labeled vancomycin (Yang et al. 2016) 
along with efflux pump inhibitors to determine if Δrip1 has defects in 
permeability or efflux. 
Of the Δrip1 stress sensitivities we identified, hypoxia in particular has been 
the subject of numerous studies which have elegantly examined the 
transcriptional response it induces. While we determined that Δrip1 shows no 
defect in inducing the DosR regulon, we did not test DosR-independent gene 
induction both in the early stages of hypoxia as well as in the later stages, 
which have been termed the enduring hypoxic response (EHR) (Rustad et al. 
2008). As Δrip1 is attenuated in both the early and later stages of the Wayne 
model, a defect in induction of the EHR or other DosR-independent pathways 
may explain of this phenotype. In particular, the sigma factors σE and σH are 
known to be induced by hypoxia, but are not part of the DosR regulon. The 
known anti-sigma factors for σE and σH are localized to the cytoplasm, but 
additional anti-sigma factors or genetic interactions with Rip1 may exist. 
As the Δrip1 phenotypes we identified are characterized by different 
requirements for catalytic activity and the PDZ domain as well as differing 
interactions with previously-identified sigma factors, it may be the case that the 
mechanism of Δrip1 sensitivity to these stresses utilizes different pathways or 
arms of the Rip1 regulon. While Δrip1’s high degree of sensitivity to antibiotics 
may be an obstacle to this approach, an unbiased genetic screen for 
suppressors of Δrip1 sensitivity to antibiotics may yield novel interactors in the 
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Rip1 pathway. Whether or not these interactors also are active in response to 
nitric oxide or hypoxia would help determine whether the sensitivities we found 
are truly attributable to a single set of players or whether multiple arms of the 
Rip1 pathway are each responsible for different phenotypes. 
In short, we identified three groups of stresses which show increased efficacy 
towards Δrip1. We characterized the requirements for catalytic activity, for the 
PDZ domain, and for previously-discovered sigma factors in resistance 
towards these stresses. We are presently unsure the degree to which these 
stresses are linked, as they show some overlap of requirements for these 
factors as well as differing responses to the reducing agent NaHS. Much work 
remains to be done characterizing the response to these stresses in the Δrip1 
setting, which may further elucidate the causes of this strain’s attenuation. 
 
Δrip1 regains a significant degree of virulence in the iNOS knockout 
mouse, and lesions in this host show several traits of granulomas 
Based on the sensitivity of Δrip1 to nitric oxide described above, we infected 
the nos2-/- (iNOS knockout) mouse with Δrip1. In the absence of this host-
mediated effector, Δrip1 is able to grow and persist to a much greater degree 
in the mouse, but it does not regain the full virulence seen in the WT strain. 
Much of the remaining phenotype of Δrip1 in this setting can be attributed to a 
defect in the acute phase of infection present from the beginning of the 
infection to week 1, which is likely dominated by the innate immune system 
and is before iNOS is thought to be induced. Additionally, this strain—unlike 
the Bl/6 mouse—is able to form hypoxic lesions, which may contribute to its 
ability to control Δrip1 during chronic infection, specifically because Δrip1 is 
defective in the hypoxic stage of infection. 
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Strikingly, histopathology performed on lungs of iNOS mice infected with Δrip1 
showed that lesions from these mice showed several characteristics of 
granulomas, including necrotic centers, an unstained ring of cells which may 
indicate foamy macrophages, a fibrotic sheath surrounding the wound, 
localization of bacteria primarily to these wounds, and positive staining for 
pimonidazole adducts which indicates hypoxia. This is atypical of mouse 
infections with M. tb, which has been a source of difficulty within the field given 
the many other advantages working with mice present. While examination of 
the literature does show that other infections of this mouse strain have yielded 
similar phenotypes (Duque-Correa et al. 2014, Cooper et al. 2000), caveats 
with the mode of infection (intraperitoneal, extremely low-dose aerosol) have 
limited the degree to which investigators have been willing to follow-up on 
these findings. We are currently uncertain the degree to which this is solely a 
phenotype of iNOS knockout mice, or whether a rip1 deletion is required to 
some or any extent in order to produce the pathology we observed. 
Mouse models which do show granulomatous pathology have been 
developed; in particular, the C3HeB/FeJ “Kramnik” mouse. This strain has 
been used in numerous studies (Driver et al. 2012, Harper et al. 2012, 
Pichugin et al. 2009, Kramnik et al. 2000) but anecdotally, issues remain, 
including mortality among infected mice and the tendency of these mice to 
form a single, central granuloma. The data we present suggests that iNOS 
mice infected with Δrip1—or perhaps other attenuated strains—may serve not 
to supplant the Kramnik mouse but as a complementary model. We observed 
mortality in mice infected with a high dose of Δrip1 and variable pathology in a 
second, low-dose infection. A third infection is ongoing, and we hope to find 
that a moderate dose yields consistent pathology without the trade-off of 
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mortality, though the lack of robustness of this model to the infectious dose is 
a concern. Additionally, as Δrip1 has pleiotropic phenotypes, this model would 
likely not be particularly useful in some settings where infection with WT M. tb 
would prove helpful, such as killing of bacteria with antibiotics in a hypoxic 
setting or at a lower dose mediated by poor diffusion across a fibrous barrier. 
To further explore the contribution of Rip1 during infection as well as to 
improve the relevance of the iNOS/ Δrip1 model, we propose to infect these 
mice with a Δrip1 knockout which conditionally expresses Rip1. We can then 
demonstrate the role of Rip1 at various phases of infection by choosing when 
to induce or not to induce expression of the complementing plasmid. 
Expression of Rip1 must be tightly regulated, as previous attempts at 
complementation of Δrip1 under an inducible promoter failed to show a Δrip1 
phenotype under uninduced conditions, likely because of low-level 
transcription without the inducer. We must also demonstrate that phenotypes 
we wish to investigate in this in vivo model are fully complemented by 
expression of Rip1 under this promoter, as we have repeatedly seen 
incomplete or partial complementation of Rip1. However, if Rip1 can be 
induced at late time points without causing mortality in the host and 
development of granulomas proceeds as seen in Δrip1 infections, we would 
then be able to consider this model with fewer caveats. 
To summarize briefly, we assessed the role of nitric oxide stress as a mediator 
of attenuation of the Δrip1 strain by infecting iNOS knockout mice with Δrip1. 
Infection of these mice restored a significant degree of virulence to Δrip1, 
though it still failed to recapitulate the full extent of virulence seen in infection 
with WT M. tb. We also found that because this strain was attenuated, it 
allowed infection of iNOS mice to proceed further than would usually happen 
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when infecting this generally M. tb-susceptible strain. As such, we were able to 
observe development of lesions in the lung which possess histopathological 
traits of human granulomas, which is atypical of the mouse model. Beyond its 
use as a tool for studying Δrip1, we believe infection of iNOS knockout mice 
possesses significant potential as a model for studying the ways in which 
pathological traits common to human disease affect the development of M. tb 
infection. 
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METHODS* 
 
Growth of mycobacteria 
M. smegmatis was grown aerobically in liquid culture in 7H9 broth (Difco) 
supplemented with 0.5% dextrose, 0.5% glycerol, and either 0.05% Tween 80 
or 0.02% Tyloxapol (7H9/smeg) and on 7H10 (Remel) agar plates 
supplemented with 0.5% dextrose and 0.5% glycerol (7H10/smeg). 7H9 
lacking biotin was made according to the listed ingredients: ammonium sulfate 
500 mg/L, monopotassium phosphate 1 g/L, disodium phosphate 2.5 g/L, 
sodium citrate 100 mg/L, magnesium sulfate 50 mg/L, calcium chloride 500 
µg/L, zinc sulfate 1 mg/L, copper sulfate 1 mg/L, L-glutamic acid 500 mg/L, 
ferric ammonium citrate 40 mg/L, pyridoxine hydrochloride 1 mg/L and 
supplemented with dextrose, glycerol, and Tween 80/Tyloxapol as above. 
7H10 lacking biotin was made according to the listed ingredients: ammonium 
sulfate 500 mg/L, monopotassium phosphate 1.5 g/L, disodium phosphate 1.5 
g/L, sodium citrate 400 mg/L, magnesium sulfate 25 mg/L, calcium chloride 
500 µg/L, zinc sulfate 1 mg/L, copper sulfate 1 mg/L, L-glutamic acid 500 
mg/L, ferric ammonium citrate 40 mg/L, pyridoxine hydrochloride 1 mg/L, 
malachite green 250 µg/L, agar 15 g/L and supplemented with dextrose and 
glycerol as above.  
M. tuberculosis was grown aerobically in liquid culture in 7H9 broth 
supplemented with 0.5% glycerol, 0.05% Tween 80, and 10% OADC 
(7H9/TB). OADC was made according to the listed ingredients and was 
adjusted to pH 7: sodium chloride 8.5 g/L, bovine serine albumin fraction V 
                                                          
* This chapter is partially derived from: Lazar et al 2017 (in review) 
 
82 
 
(Roche) 50 g/L, dextrose 20 g/L, oleic acid 600 µL/L, catalase 30 mg/L 
(Sigma). Cultures were grown as 50 mL cultures in a 490 cm2 roller bottle 
(Corning) rolled at 2 RPM.M. tuberculosis was grown on 7H10 agar plates 
(7H10/TB) supplemented with 0.5% glycerol and 10% OADC.  
Antibiotics were added at the following concentrations for mycobacteria: 20 
µg/mL kanamycin, 20 µg/mL streptomycin, 50 µg/mL hygromycin. 
Supplements were added at the following concentrations: 50 ng/mL 
anhydrotetracycline (ATc), 500 ng/mL desthiobiotin (DTB), 500 ng/mL biotin, 1 
µg/mL avidin. 
 
Transposon insertional mutagenesis 
A library of transposon insertion mutants in M. smegmatis was generated as 
described previously (Siegrist and Rubin 2009). Briefly, a 50 mL culture of 
mc2155 M. smegmatis was grown aerobically to log phase (OD 0.5-1) in 
(7H9/smeg). The culture was washed twice in 50 mL of mycobacteriophage 
buffer (MP Buffer) (50mM Tris [pH 8.0], 150 mM NaCl, 10mM MgCl2, 2 mM 
CaCl2), and then resuspended in 5mL MP buffer at 37°C. Cells were 
transduced with φMycoMarT7 at a multiplicity of infection (MOI) of 10 for one 
hour, and then were transferred to 150 mm diameter 7H10/smeg plates 
supplemented with kanamycin and incubated for three days at 37°C. A small 
aliquot was serially diluted 10-fold and cultured on 7H10/smeg plates with 
kanamycin to determine the overall frequency of tn mutagenesis in the library. 
10,000 kanamycin resistant tn mutants were pooled and then frozen at -80°C. 
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Screening and transposon insertion mapping 
Aliquots of the transposon insertional mutant library generated above were 
diluted to a cell density to yield single colonies on 150 mm 7H10/smeg plates 
supplemented with kanamycin. Individual colonies were patched onto 
7H10/smeg medium lacking biotin but with 1 µg/mL avidin and onto 
7H10/smeg medium with biotin. tn mutants which grew on medium containing 
biotin but not on medium lacking biotin were retested for biotin auxotrophy and 
confirmed auxotrophs were processed for transposon mapping as described 
previously (Siegrist and Rubin 2009). Briefly, biotin auxotrophs were grown to 
log phase and genomic DNA was prepared. Genomic DNA was digested with 
SacII restriction endonuclease (NEB) overnight and fragments were self-
ligated using T4 DNA ligase (NEB) overnight. The reaction was dialyzed, 
transformed into competent DH5α λpir E. coli, plated on LB agar 
supplemented with 40 µg/mL kanamycin, and incubated overnight at 37°C. A 
single colony was picked and used to inoculate a 5 mL culture of liquid LB 
broth supplemented with kanamycin. Plasmid DNA was prepared, and the 
insertion site was sequenced using primers (oNZL003/004) which anneal to 
the transposon sequence. 
 
Growth of on solid medium lacking biotin 
Strains were grown in 7H9/smeg medium with appropriate antibiotics to log 
phase, then washed three times in 7H9/smeg, with avidin substituted for biotin. 
ODs were normalized to a starting OD of 0.1, and then serial dilutions were 
spotted onto solid medium (spots 2-5 µL). Agar media cultures were incubated 
at 37°C for three days. 
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Growth in liquid medium lacking biotin 
Strains were grown in 7H9/smeg medium with appropriate antibiotics to log 
phase, then washed three times in 7H9/smeg reconstituted using its 
components, but omitting biotin. Cultures were inoculated to a starting OD of 
0.075 at 150 µL per well in a 96 well flat-bottomed clear microplate (Corning) 
in medium containing 1x (500 ng/mL), 1/10x, 1/100x, 1/1000x, or 0 biotin. 
Each strain/condition was repeated in triplicate. The microplate was incubated 
at 37°C for 36 hours in a Tecan M1000 plate reader constantly shaking at a 6 
mm amplitude in orbital mode. OD600 readings were taken every 30 minutes 
for the duration of the experiment. 
 
Sequence alignment 
Sequence alignment was performed using the Clustal Omega web form 
(McWilliam et al. 2013, Sievers et al. 2011). Biotin carboxylase catalytic 
residues were identified via homology with the E. coli biotin carboxylase, 
(Janiyani et al. 2001) carboxytransferase catalytic residues were identified via 
homology with the S. aureus pyruvate carboxylase (Yu et al. 2009), and the 
biotin attachment residue was identified via the CDD database (Marchler-
Bauer et al. 2017). Domain architecture was identified by homology to the R. 
etli pyruvate carboxylase (St Maurice et al. 2007). 
 
Western blot analysis 
Protein lysates were made from M. smegmatis cultures grown to mid-log 
OD600, then washed three times in 7H9/smeg broth made without biotin but 
including avidin, then resuspended to various ODs such that the culture would 
reach OD 0.6 after biotin deprivation (OD 0.3 for 3h deprivations and 0.15 for 6 
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and 12 hour deprivations). Cultures were pelleted by centrifugation at 3000g 
for ten minutes, then supernatant was aspirated and the pellets were frozen 
overnight at -80°C. Pellets were resuspended in lysis buffer (50 mM Tris-HCl 
[pH 8.0], 50 mM NaCl, 2% SDS, 2 mM EDTA, 1 mM DTT, 1 mM PMSF) and 
lysed by bead beating with 0.1 mm zirconia beads in a Biospec Mini-
Beadbeater-16 3 times for 45s each. Samples were centrifuged at 3000g for 
10 minutes and soluble protein concentration in the supernatant was 
quantified by absorbance at 280 nm in a NanoDrop 1000 (Thermo). Samples 
were added 1:1 to 2x SDS sample buffer (20% glycerol, 125 mM Tris [pH 6.8], 
4% SDS, 0.2% bromphenol blue, 100 mM DTT), boiled for 10 minutes, then 
cooled on ice before loading equal quantities of protein into a 4-12%  NuPage 
Bis-Tris protein gradient gel (Thermo Fisher). Gels were run using MOPS SDS 
running buffer (Thermo Fisher) for 80 minutes at 150 V before being 
transferred to a Protran nitrocellulose membrane (Whatman) using a Trans-
Blot semi-dry apparatus (Bio-Rad). Biotinylated protein was detected using 
streptavidin-HRP 
 
Metabolomics 
Metabolites were detected using LC-MS on samples prepared from M. 
smegmatis cultures grown on nitrocellulose filters as performed previously 
(Puckett et al. 2017, Eoh and Rhee 2013, de Carvalho et al. 2010). Strains 
were grown to mid-log OD in 7H9/smeg and then inoculated onto 0.22 µM 
nitrocellulose filters under vacuum filtration. Experiments were done in 
triplicate. Filters were placed on top of 7H10/smeg agar plates and allowed to 
grow at 37°C for two days, followed by transfer to 7H10/smeg agar plates 
made with biotin or without biotin and with avidin for three hours. Filters were 
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transferred to methanol/acetonitrile/water (2:2:1) precooled on dry ice to 
metabolically quench the bacteria and bacteria were scraped off of filters. 
Cells were lysed by bead beating with zirconia beads, centrifuged, and 
supernatants were filtered across 0.22 µM filters.  LC-MS was performed with 
an Agilent Accurate Mass 6220 TOF coupled with an Agilent 1200 Liquid 
Chromatography system using a Cogent Diamond Hydride Type C as 
described previously (Eoh and Rhee 2013). Metabolites were identified based 
on unique accurate mass-retention time identifiers for masses exhibiting the 
expected distribution of accompanying isotopomers. 
Metabolites were normalized to overall biomass using a generalized linear 
regression model which takes into account that most metabolites remain 
unchanged (Boyle et al. under review). Statistical analysis was performed 
using ANOVA for fixed effects on a linear mixed-effects model. The threshold 
of significance was adjusted for multiple hypotheses testing using the 
Bonferroni correction. 
 
Reverse transcription-quantitative PCR 
Relative mRNA levels were identified using reverse transcriptase-quantitative 
PCR (RT-qPCR). M. smegmatis cultures were grown to mid log OD and either 
not treated (+ biotin) or washed three times in 7H9/smeg lacking biotin and 
containing avidin before being resuspended in medium lacking biotin. All 
cultures were inoculated in triplicate to an OD of 0.3 and incubated at 37°C for 
three hours before being centrifuged at 3000g. The supernatant was aspirated 
and cells were frozen overnight at -80°C. Cells were lysed and RNA prepared 
using a GeneJET RNA Purification kit (Thermo) following the bacteria total 
RNA purification protocol with alterations. Before lysis, cells were resuspended 
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in 200 µL Tris-EDTA (TE) buffer supplemented with 1 mg/mL lysozyme. Cells 
were disrupted by beat beating with zirconia beads, and protein was digested 
with proteinase K for 5 minutes at room temperature. Lysis buffer was added 
and the mixture was vortexed, then ethanol was added and the mixture was 
centrifuged at 3000g. The supernatant was added to a GeneJET RNA 
purification column and the protocol followed as written. 
M. tuberculosis cultures were grown to mid-log OD and were treated with 50 
µM DETA-NO for 40 minutes (or not treated). Treatment was performed in 
triplicate. Cultures were centrifuged at 3000g and the supernatant was 
aspirated. Pellets were resuspended in Trizol reagent (Invitrogen). Cells were 
disrupted mechanically by bead beating with zirconia beads. RNA was 
extracted with chloroform, precipitated with isopropanol, washed with 70% 
ethanol, and then dried before being resuspended in water. 
cDNA was synthesized using a Thermo Maxima First Strand cDNA synthesis 
kit with dsDNAse, using 500 ng of RNA per sample. qPCR was performed 
using a Thermo Scientific DyNAmo Flash Probe qPCR kit and TaqMan 
reagents on an Applied Biosystems 7500 quantitative PCR machine. Single 
amplifications were confirmed by the presence of a melting curve with a single 
peak, and the absence of contaminating genomic DNA was confirmed by the 
absence of amplification in control cDNA synthesis reactions performed 
without RT. The cycle threshold (CT) value observed for each sample was 
normalized to the endogenous control value observed for the housekeeping 
gene sigA using the formula ΔCT = CT; gene - CT; sigA. Normalized expression 
levels for each gene and condition were calculated using the formula 2(−ΔCT). 
 
 
88 
 
Construction of mutants using CRISPR 
Human codon-optimized Cas9 from pX330 (Cong et al. 2013) was cloned 
using a “dual control” system (Kim et al. 2013) under a tight 
anhydrotetracycline-dependent promoter with a mutated ribosome-binding site 
(SD5) (Woong Park et al. 2011) to produce an inducible plasmid (pAJF658) 
and integrated into the M. smegmatis genome at the L5 phage attB site. 
crRNA containing 20 nucleotides of homology to the desired cut site was fused 
to tracrRNA present on an episomal plasmid (pAJF619) to form a single guide 
RNA (sgRNA). The resultant vector was transformed into strains already 
containing pAJF658. Parent strains containing both pAJF658 and pAJF619 
were grown to mid-log OD, induced with ATc for three hours or not induced for 
controls, and was cultured on 7H10/smeg plates containing and lacking ATc. 
Individual surviving colonies were picked for inductions which produced 
approximately 10-fold or more killing and colony PCR was performed to 
amplify the genomic DNA region surrounding the sgRNA targeted site. PCR 
products were treated with ExoSAP-IT (Thermo) and sequenced. 
 
Construction of mutants using homologous recombination and double 
counterselection 
Mutants were constructed using the method described in (Barkan, Stallings, 
and Glickman 2011). Briefly, plasmids were constructed containing 500 bp 
flanking regions 5’ and 3’ of the gene to be deleted. Plasmids also contained a 
hygromycin resistance cassette, as well as galK and sacB genes to be used 
for double counterselection. The plasmids lacked a mycobacterial origin of 
replication to prevent replication of the plasmid without integration via 
homologous recombination. Plasmids were transformed into parent strains 
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and intermediates were selected by resistance to hygromycin. Integrated 
plasmids were counterselected using 0.2% 2-deoxy-galactose (2-DOG) and 
5% sucrose. Recombinations which produced genetic deletions were 
confirmed via southern blot. 
 
Tests of sensitivity to in vitro stresses 
M. tb cultures were grown to mid-log OD before being exposed to stresses, or 
not exposed as a control: 10 mM hydrogen peroxide, 4h exposure. 2.5 mg/mL 
lysozyme, 2h. 0.05% SDS, 2h. Acidified 7H9/TB medium, pH 4.5, 7d. 200 µM 
DETA-NO (Cayman Chemical) added daily, 3d. Cultures were exposed to 
stresses as 10 mL cultures in 30 mL PETG inkwell bottles (Nalgene) shaking 
at 150 RPM. Cultures were plated on 7H10/TB plates and incubated at 37oC 
for 3 weeks before CFUs were enumerated. Exposures were performed in 
triplicates. 
 
MIC Determination 
Cultures were grown to mid-log OD before being exposed to stress or 
antibiotic. Cultures were diluted to OD 0.01 in 96-well plates with 200 µL 
culture volumes, excluding the outer wells, which were filled with water to 
minimize the effect of evaporation. Stress was added over a range of 2-fold 
dilutions. Cultures were exposed in triplicate. Plates were wrapped in parafilm 
and then added to a sealable plastic container before being incubated at 37oC 
without shaking for one week. MICs were determined as the minimum 
concentration of stress or antibiotic necessary to prevent a visible pellet from 
forming. Strains were added to plates in triplicate. 
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Loebel model 
Cultures were grown to mid-log OD before being washed three times in PBS. 
Cultures were resuspended in PBS at OD 0.05, and then added as 50 mL 
cultures in 650 mL suspension culture flasks incubated at 37oC on their sides. 
Cultures were grown in triplicates. Cultures were plated on 7H10/TB plates 
and incubated at 37oC for 3 weeks before CFUs were enumerated. 
 
Wayne model 
Wayne model experiments were performed as previously described (Wayne 
and Hayes 1996) with alterations. Briefly, cultures were grown to mid-log OD. 
Cultures were diluted to OD 0.005 in 7H9/TB. 17mL of cultures was added to 
sterile 20x125mm borosilicate glass tubes (Fisher) with a 1.5x8mm Teflon-
coated stir bar (Fisher). 9 µg/mL methylene blue was added to one of three 
replicates to indicate hypoxia via decolorization. Tubes were tightly sealed with 
a rubber stopper, placed in a tube rack, and then stirred using a Wheaton 
Biostir stirring at 150 RPM and incubated at 37oC. 
To remove culture from the tube without introducing air, we withdrew culture 
using a 1 mL tuberculin syringe and an intradermal bevel 26Gx 3/8 precision 
glide needle (BD). Culture was plated on 7H10/TB plates and incubated at   
37oC for 3 weeks before CFUs were enumerated. 
 
Construction of mutants 
Mutants in M. tb were constructed using specialized transduction using the 
temperature sensitive phage phAE87 (Bardarov et al. 1997, Barkan et al. 
2009). Rip1 was deleted by allelic exchange with hygR. M. tb ΔRv2625c was 
grown to OD 0.8 and then infected with phage at an MOI of 10 for 4h at 37oC. 
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Hygromycin-resistant colonies were selected and genomic DNA was prepared 
for screening by Southern blotting.  
 
Infection of mice 
Strains were grown to mid-log OD, washed twice in PBS/0.05% Tween 80, 
and sonicated to disperse clumps, before being diluted in sterile water to OD 
0.016. Mice were exposed to 4 × 107 CFU in a Middlebrook Inhalation 
Exposure System (Glas-Col). This dose of bacteria delivers 100 CFU per 
animal. Bacterial burden was determined by plating lung or spleen 
homogenates on 7H10/TB plates. Organs were homogenized using a Bullet 
Blender 5E homogenizer to bead beat organs in 2-4 mL of PBS/0.05% Tween 
80 in 5mL tubes. Lungs were homogenized for 4 minutes at speed 8; spleens 
were homogenized for 8 minutes at speed 8.  For histology, lungs were fixed 
in 10% phosphate buffered formalin for 24 hours at 4oC before being washed 
in water, washed in ethanol, embedded in paraffin and stained. 
 
Injection with pimonidazole 
Mice were injected with 100 µL 15 mg/mL pimonidazole (Hypoxyprobe) 
suspended in water via the intraperitoneal route with a 1/2 cc U-100 insulin 
syringe with a permanently attached 28G ½ (0.36mm x 13mm) needle (BD). 
Mice were sacrificed 1-1.5 hours after injection, and embedded lung sections 
were stained with an anti-pimonidazole antibody conjugated to HRP and 
counterstained with hematoxylin.  
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APPENDIX A: LIST OF OLIGONUCLEOTIDES 
 
Name Sequence Relevant Features 
oNZL003 GCCTTCTTGACGAGTTCTTCTGAG 
sequencing of transposon insertions 
(F direction) 
oNZL004 CCGAGATAGGGTTGAGTGTTGTTC 
sequencing of transposon insertions 
(R direction) 
oCrBioQ-1F CACCCTGGCATTTCGCCAACAAAC crRNA deletion of bioQ 
oCrBioQ-1R AAACGTTTGTTGGCGAAATGCCAG crRNA deletion of bioQ 
oCrBioQ-2F CACCGAGATCGTGGAGCAGC crRNA deletion of bioQ 
oCrBioQ-2R AAACGCTGCTCCACGATCTCGGTG crRNA deletion of bioQ 
oBioF-F CACCCGACATCGTGATGAC 
primer for qPCR amplification of bioF 
(F direction) 
oBioF-R CGGTGTCGAAGATGAAC 
primer for qPCR amplification of bioF 
(R direction) 
oBioF-taq CACGACGCTGTCGAAAGCACTG 
taqMan probe for qPCR quantitation 
of bioF 
oBioA-F CTGGACACGGTGTTCTTC 
primer for qPCR amplification of bioA 
(F direction) 
oBioA-R TCATCAACCGGTGCTTGG 
primer for qPCR amplification of bioA 
(R direction) 
oBioA-taq TGGAGGTCGCGGTGAAGATG 
taqMan probe for qPCR quantitation 
of bioA 
oBioD-F ACCGCATTGACCCTCGAAG 
primer for qPCR amplification of 
bioD (F direction) 
oBioD-R ATCCAGTCTGCGTCAAAC 
primer for qPCR amplification of 
bioD (R direction) 
oBioD-taq CGAACGCTTCGAGGCGTTGAG 
taqMan probe for qPCR quantitation 
of bioD 
oBioB-F CATCATCAGCCTCAAGAC 
primer for qPCR amplification of bioB 
(F direction) 
oBioB-R TTCGGTGGCACCGGTCTTTG 
primer for qPCR amplification of bioB 
(R direction) 
oBioB-taq TGCCACTTCTGCTCGCAGT 
taqMan probe for qPCR quantitation 
of bioB 
oSigA-F TGAGGTGACCGACGATCT 
primer for qPCR amplification of M. 
smegmatis sigA (F direction) 
oSigA-R GGCATCAGCTTCTTCTTCCT 
primer for qPCR amplification of M. 
smegmatis sigA (R direction) 
oSigA-taq AAGACACCGACCTGGAACTCG 
taqMan probe for qPCR quantitation 
of M. smegmatis sigA 
oTBSigA-F CGACGAAGACCACGAAGAC 
primer for qPCR amplification of M. 
tuberculosis sigA (F direction) 
oTBSigA-R TTTCGGTGGGTTCAGCGATCTCC 
primer for qPCR amplification of M. 
tuberculosis sigA (R direction) 
oTBSigA-taq CGTCTTCATCCCAGACGAAATC 
taqMan probe for qPCR quantitation 
of M. tuberculosis sigA 
o2625c-F TCTTGATCGCGTTGGGATTG 
primer for qPCR amplification of 
Rv2625c (F direction) 
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APPENDIX A (continued) 
 
 
o2625c-taq CGAAGACGCCAGCAAGGACATCAG 
taqMan probe for qPCR quantitation 
of Rv2625c 
o2625c-R CCCGGCGAATTGATGTAGAG 
primer for qPCR amplification of 
Rv2625c (R direction) 
oDosR-F TCTGATCCTCACGTCCTACAC 
primer for qPCR amplification of 
dosR (F direction) 
oDosR-taq TGCCAGCGGATATGTCGTCAAAG 
taqMan probe for qPCR quantitation 
of dosR 
oDosR-R AGCGCCCACATCTTTGAC 
primer for qPCR amplification of 
dosR (R direction) 
oHspX-F GAATTCGCGTACGGTTCCTTC 
primer for qPCR amplification of 
hspX (F direction) 
oHspX-taq ATTAAGGCCACCTACGACAAGGG 
taqMan probe for qPCR quantitation 
of hspX 
oHspX-R GCCACCGACACAGTAAGAATG 
primer for qPCR amplification of 
hspX (R direction) 
oClpP1-F GTTATGCGCTCAGATTCTGC 
primer for qPCR amplification of 
clpP1 (F direction) 
oClpP1-taq CGAAGACGCCAGCAAGGACATCAG 
taqMan probe for qPCR quantitation 
of clpP1 
oClpP1-R CCCGGCGAATTGATGTAGAG 
primer for qPCR amplification of 
clpP1 (R direction) 
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APPENDIX B: LIST OF PLASMIDS 
 
Name Relevant Features 
pMSG419 
TET-ON dependent expression vector with a polylinker for N-
terminal HA fusions hygR oriM oriE 
pNZL035 pMSG419 / MSMEG_2412 
pNZL036 pMSG419 / MSMEG_2413 
pNZL037 pMSG419 / MSMEG_2414 
pNZL106 
TET-ON dependent expression vector with a polylinker for N-
terminal HA fusions strepR oriM oriE 
pNZL035. 
strep pNZL106 / MSMEG_2412 (pyruvate carboxylase) 
pNZL065 
pNZL106 / MSMEG_6648 (other annotated M. smegmatis 
pyruvate carboxylase) 
pNZL070 pNZL106 / Rv2967c (M. tuberculosis pyc) 
pNZL107 
pNZL106 / MSMEG_2412 biotin carboxylase (BC) domain (2412 
residues 1-441) 
pNZL108 
pNZL106 / MSMEG_2412 carboxytransferase (CT) domain (2412 
residues 498-965) 
pNZL109 
pNZL106 / MSMEG_2412 CT + biotin binding (BCCP) domain 
(2412 residues 498-1128) 
pNZL154 
pNZL106 / MSMEG_2412 E288K biotin carboxylase catalytic site 
mutant 
pNZL163 pNZL106 / MSMEG_2412 K1093L biotin attachment site mutant 
pNZL164 pNZL106 / MSMEG_2412 K1093R biotin attachment site mutant 
pNZL156 pNZL106 / MSMEG_3188 (BioA) 
pNZL159 pNZL106 / MSMEG_3194 (BioB) 
pAJF658 
TET-ON dependent expression vector with a DAS tag for Dual 
Control / hCas9  hygR oriE  int attP 
pAJF619 tracrRNA parent plasmid strepR oriE oriM  
pBioQ-1 pAJF619 fused to oCrBioQ-1F/R via oligonucleotide ligation 
pBioQ-2 pAJF619 fused to oCrBioQ-2F/R via oligonucleotide ligation 
pMV261. 
kan Episomal mycobacterial vector kanR oriM oriE 
pHMG121 pMV261.kan / Rip1 (Rv2869c) 
pHMG221 pMV261.kan / Rip1H21A 
pMSG395 pMV261.kan / Rip1ΔPDZ 
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Strain 
number Description 
Genotype/ 
Relevant Features Reference 
MGM8000 WT 
Wild Type M. smegmatis 
mc2155 Laboratory collection 
MGM8001 m10 Mc2155 MSMEG_2412::tn  this work 
MGM8002 m35 Mc2155 bioB::tn this work 
MGM8003 m43 Mc2155 bioF::tn this work 
MGM8004 m86 Mc2155 bioA::tn this work 
MGM8005 m119 Mc2155 MSMEG_2412::tn  this work 
MGM8006 m134 Mc2155 MSMEG_2412::tn  this work 
MGM8007 WT + EV Mc2155 / pMSG419 this work 
MGM8008 pyc::tn + EV MGM8006 / pMSG419 this work 
MGM8009 bioA::tn + EV MGM8004 / pMSG419 this work 
MGM8010 bioB::tn + EV MGM8002 / pMSG419 this work 
MGM8011 pyc::tn + pPyc MGM8006 / pNZL035 this work 
MGM8012 pyc::tn + p2413 MGM8006 / pNZL036 this work 
MGM8013 pyc::tn + p2414 MGM8006 / pNZL037 this work 
MGM8019 WT + EV Mc2155 / pNZL106 this work 
MGM8020 pyc::tn + EV MGM8006 / pNZL106 this work 
MGM8021 bioA::tn + EV MGM8004 / pNZL106 this work 
MGM8023 pyc::tn + pPyc MGM8006 / pNZL035.strep this work 
MGM8024 pyc::tn + p6648 MGM8006/ pNZL065 this work 
MGM8025 pyc::tn + pRv2967c MGM8006/ pNZL070 this work 
MGM8026 
pyc::tn + pPyc  
(BC domain) MGM8006 / pNZL107 this work 
MGM8027 
pyc::tn + pPyc  
(CT domain) MGM8006 / pNZL108 this work 
MGM8028 
pyc::tn + pPyc (CT + 
BCCP domains) MGM8006 / pNZL109 this work 
MGM8029 pyc::tn + pPyc-E288K MGM8006 / pNZL154 this work 
MGM8030 pyc::tn + pPyc-K1093L MGM8006 / pNZL163 this work 
MGM8031 pyc::tn + pPyc-K1093R MGM8006 / pNZL164 this work 
MGM8034 pyc::tn + pBioA MGM8006 / pNZL156 this work 
MGM8035 pyc::tn + pBioB MGM8006 / pNZL159 this work 
MGM8036 bioA::tn + pBioA MGM8004 / pNZL156 this work 
MGM8037 bioA::tn + pBioB MGM8004 / pNZL159 this work 
MGM8041 bioQ mutant #16 
MGM8006 bioQ frameshift 
138-139 A this work 
MGM8050 Δrip1/ΔRv2625c 
EF2 Δrip1::loxP  
ΔRv2625c:: hyg this work 
MGM8051 Δrip1/ΔRv2625c + pEV MGM8050 / pMV261.kan this work 
MGM8052 ΔσKLM + pEV MGM3256 / pMV261.kan this work 
MGM8053 ΔσD + pEV   MGM-JSS005 / pMV261.kan this work 
MGM6514 Δpyc Mc2155 MSMEG_2412::hyg this work 
MGM6516 ΔbioQ Mc2155 bioQ::hyg this work 
MGM6520 pyc::tn / ΔbioQ MGM8006 bioQ::hyg this work 
MGM6521 Δpyc + EV MGM6514 / pNZL106 this work 
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MGM6522 Δpyc + pNZL107 MGM6514 / pNZL107 this work 
MGM6523 Δpyc + pNZL108 MGM6514 / pNZL108 this work 
MGM6524 Δpyc + pNZL109 MGM6514 / pNZL109 this work 
MGM6525 Δpyc + pNZL154 MGM6514 / pNZL154 this work 
MGM6526 Δpyc + pNZL163 MGM6514 / pNZL163 this work 
MGM6527 Δpyc + pNZL164 MGM6514 / pNZL164 this work 
EF2 WT  M. tuberculosis Erdman Laboratory collection 
MGM309 Δrip1 EF2 Δrip1::hyg 
(Makinoshima and 
Glickman 2005) 
MGM345 WT + pEV EF2 / pMV261.kan (Sklar et al. 2010) 
MGM349 Δrip1 + pEV EF2 Δrip1::hyg / pMV261.kan (Sklar et al. 2010) 
MGM350 Δrip1 + pRip1 EF2 Δrip1::hyg / pHMG121 (Sklar et al. 2010) 
MGM705 ΔRv2625c + pEV 
EF2 ΔRv2625c::hyg / 
pMV261.kan (Sklar et al. 2010) 
MGM573 Δrip1 + pRip1-H21A EF2 Δrip1::hyg / pHMG221 (Sklar et al. 2010) 
MGM575 Δrip1 + pRip1ΔPDZ EF2 Δrip1::hyg / pMSG395 
(Schneider et al. 
2013) 
MGM3256 ΔσKLM 
EF2 ΔσL::loxP ΔσM::hyg 
ΔσK::zeo 
(Schneider, Sklar, 
and Glickman 2014) 
MGM-
JSS005 ΔσD EF2 ΔσD::hyg 
(Schneider, Sklar, 
and Glickman 2014) 
MGM3206 Δrip1 cured EF2 Δrip1::loxP 
(Schneider, Sklar, 
and Glickman 2014) 
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